

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11)



EP 0 702 551 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**25.09.2002 Bulletin 2002/39**

(51) Int Cl.7: **A61K 31/44, A61K 31/47,**  
**A61P 19/04**

(21) Application number: **94916710.0**

(86) International application number:  
**PCT/US94/05156**

(22) Date of filing: **09.05.1994**

(87) International publication number:  
**WO 94/026249 (24.11.1994 Gazette 1994/26)**

### (54) COMPOSITIONS AND METHODS FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR REPARATUR UND VORBEUGUNG  
FIBROTISCHER VERLETZUNGEN

COMPOSITIONS ET PROCEDES DE REPARATION ET DE PREVENTION DE LESIONS DU TYPE  
FIBROSE

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT  
SE**

(74) Representative: **Harrison, Ivor Stanley et al  
Withers & Rogers,  
Goldings House, 2 Hays Lane  
London SE1 2HW (GB)**

(30) Priority: **07.05.1993 US 59214  
19.05.1993 US 64831**

(56) References cited:  
**EP-A- 0 383 591** **US-A- 3 974 281**  
**US-A- 4 042 699** **US-A- 5 310 562**

(43) Date of publication of application:  
**27.03.1996 Bulletin 1996/13**

#### Remarks:

The file contains technical information submitted  
after the application was filed and not included in this  
specification

(73) Proprietor: **MARGOLIN, Solomon B.  
Dallas, TX 75225 (US)**

(72) Inventor: **MARGOLIN, Solomon B.  
Dallas, TX 75225 (US)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description****Technical Field of the Invention**

5 [0001] The present invention relates to medical compositione and methods for the reparation of fibrotic lesional tissues and the prevention of fibrotic lesions, which compositions comprise one or more N-substituted 2(1H) pyridones and/or one or more N-substituted 3(1H) pyridones as active anti-fibrotic ingredient(s).

**Background Art**

10 [0002] Herein, the term "anti-fibro", "anti-fibrotic" or "anti-fibrosis" refers to the reparations and/or prevention of pathological polymerization of collagen in lung fibrosis, arteriosclerosis, prostatic hypertrophy, keloid, myocarditis, collagen disease, scar, wrinkle, etc., and reparation as well normalization of the existing pathological fibrotic tissues.

15 [0003] Methods of preparation of some N-substituted 2(1-H) pyridones useful in the present invention are described in US Patent No. 3,839,346, issued October 1, 1974, to Gadekar, and titled N-SUBSTITUTED PYRIDONE AND GENERAL METHOD FOR PREPARING PYRIDONES. That patent also describes use of those compounds in analgesic, anti-inflammatory, and antipyretic treatments. US Patents Nos. 3,974,281, issued August 10, 1976; 4,042,699, issued August 16, 1977; and 4,052,509, issued October 4, 1977, all to Gadekar, describe further use of one of these compounds, 5-methyl-1-phenyl-2-(1H) pyridone ("pirfenidone"), in lowering serum uric acid and glucose levels, treating upper respiratory inflammatory conditions, and treating inflammatory skin conditions, in humans and other mammals.

20 [0004] The use of pirfenidone in the reparation and prevention of fibrotic lesions is described in EP-A-0 383 591.

[0005] It has been discovered by the present inventor that other N-substituted 2(1-H) pyridone compounds and N-substituted 3(1H) pyridone compounds also have anti-fibrotic activity. Heretofore, before the discoveries of the inventions disclosed herein and in the above copending applications, no effective pharmacological agent or composition has been available for the prevention or removal of pathologic fibrotic lesions of the lungs, prostate glands, musculoskeletal diseases, myocardial degeneration, myocardial infarction, arteriosclerosis, and other lesional fibroses.

25 [0006] For example, powerful anti-inflammatory glucocorticoids (hormones relating to carbohydrate metabolism) such as hydrocortisone or prednisolone administered in very large doses have repeatedly been shown to be ineffective against fibrotic disease. These glucocorticoids do not arrest or remove such life-threatening fibrotic lesions. The glucocorticoids may be effective, however, as anti-inflammatory agents under such condition that they may temporarily ameliorate the secondary acute inflammation flare-ups which intermittently occur in tissues or organs damaged by fibrotic disease. Indeed, excessive and prolonged administration of glucocorticoids in pulmonary fibrotic disease may cause destruction of tissues, due to fibrosis or an exacerbation and acceleration of the fibrotic destruction.

30 [0007] Antopol (1950) was the first of many investigators who found that the anti-inflammatory glucocorticoids readily enhance fibrotic degeneration of lung tissues. Similarly, the non-steroidal anti-inflammatory agents such as aspirin, salicylates, phenylbutazone, indomethacin, various phenylacetic acid derivatives, and the like have also failed to arrest formation of, or cause repair of progressive, chronic fibrotic damage to lung tissues, prostatic tissues, musculoskeletal tissues, etc.

35 [0008] Accordingly, it is a principal object of the present invention to provide compositions for the reparation and prevention of fibrotic lesional tissue.

40 [0009] It is an additional object of the invention to provide such compositions that comprise one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s) as active anti-fibrotic ingredient(s).

45 [0010] Other objects of the present invention, as well as particular features and advantages thereof, will be elucidated in, or be apparent from, the following description.

**Disclosure of Invention**

50 [0011] The present invention provides the use of a compound selected from 3-methyl-1-phenyl-2-(1H)-pyridone, 6-methyl-1-phenyl-2-(1H) pyridone, 3,6-dimethyl-1-phenyl-2-(1H) pyridone, 5-ethyl-1-phenyl-2-(1H) pyridone, 1-phenyl-2-(1H)-pyridone and 1,3-diphenyl-5-methyl-2-(1H)-pyridone in the preparation of a medicament for the reparation and prevention of fibrotic lesional tissue in a mammal.

**Best Mode for Carrying Out the Invention**

55 [0012] The "anti-fibrotic" activity described herein differs from "fibrinolytic" or "anti-fibrin" activity. The fibrinolytic" or "anti-fibrin" activity refers to the biological ability of a pharmaceutical substance to (1) prevent fibrin formation (prevent formation of a blood clot) or (2) lyse or dissolve a previously formed blood clot.

[0013] The "anti-fibrotic" activity discovered by the present inventor and as used herein refers to the ability of an

active substance to (1) prevent an excessive pathologic accumulation of collagenous scar or connective tissue in various body structures and organs (usually triggered by some injury, allergy, infection, or by some inherited genetic aberration), or (2) cause the non-surgical removal or biological dissolution of an existing excessive and pathologic accumulation of fibrotic collagenous tissue (for example, as in the dissolution of life-threatening fibrotic lesions of the lung found in patients with asbestosis).

#### A. CONNECTIVE TISSUE PROTEINS OF MAMMALS

[0014] Three major classifications of connective tissue proteins are recognized with the largest portions consisting of collagen types (70 to 80%) and elastin types (15 to 20%). A miscellaneous group constitutes the third and smallest class.

[0015] The general biochemical characteristics of the collagen types which constitute the principal protein (1) in normal white connective tissue and (2) in scar or fibrotic tissue, are summarized in Table 1, as contrasted with elastin types. For example, collagen is sparingly soluble in water, but readily converted to water soluble gelatin upon boiling in an acid or alkali. In contrast, the highly water soluble elastin does not convert to gelatin upon boiling in an acid or alkali.

[0016] The elastin constitutes the principal protein of yellow connective tissue found in elastic structures such as the walls of larger blood vessels and walls of lung alveoli.

[0017] Investigations on the molecular biochemical level of tissues have demonstrated a very slow turnover rate for metabolic processes involving fibrotic lung collagen. In fact, the metabolic rate is measured in years. By contrast, the metabolic rates of the other connective tissue collagens including elastin and the like are measured and expressed in hours and days (White, Handler, and Smith, 1973, page 983).

#### B. INTERSTITIAL PROLIFERATION (HYPERPLASIA) OF FIBROBLAST-TYPE CELLS IN LUNGS AND OTHER ORGAN TISSUES

[0018] The synthesis of various collagens found in scar or fibrotic structures takes place in fibroblast cells, or fibroblast-like cells, which then extrude the collagen into the surrounding matrix. During this wound repair process, number of fibroblasts at the site, and (2) a sharp rise in the rate of the synthesis and extrusion of collagen. If these two phenomena are not prevented, the pathologic and progressive accumulation of collagen would cause polymerization and fibrotic disease (for example, impairment of respiratory function, impaired circulatory function via fibrotic changes in arterial walls, fibrotic degeneration of renal and liver function, degenerative musculoskeletal function, fibrotic degeneration of cardiac muscle or skeletal muscle, fibrotic degenerative changes in neuronal tissues in the central nervous system as well as the peripheral nervous system, etc.). [S. L. Robbins, R. S. Cotran, V. Kumar, "Pathologic Basis of Disease", 6th edition, pages 40-84, Saunders, Philadelphia, Pennsylvania (Pub.)].

[0019] With pulmonary interstitial fibrotic hyperplasia, small and firm nodules are palpable throughout the lung tissue, and upon gross examination are recognized from their opaque, airless structure to be foci of abnormal accumulations of fibrotic connective tissue. Such foci vary in size and color according to their age. Their aggressive and continued enlargement and coalescence ultimately leads to collagenous solidification of large segments of the lungs.

[0020] These enlarging foci also impinge upon the lung capillaries thereby to reduce pulmonary blood flow, and at the same time, impede lymphatic drainage from the lungs. As a consequence, exudate accumulates within the alveoli, and secondary thickening of the alveolar wall ensues. These interacting processes sharply reduce the efficiency of the gaseous exchange in the lung alveoli, which is a primary function of the normal lung.

[0021] In addition, these pulmonary fibrotic alterations and accumulations raise the pulmonary blood vessel resistance and lead to cor pulmonale (sharply elevated pulmonary blood pressure). Prolonged elevated pulmonary blood pressure almost invariably leads to congestive heart failure in addition to the cyanosis caused by inadequate pulmonary exchange of oxygen and carbon dioxide. The prognosis is poor and the incidence of severe morbidity and deaths is high.

[0022] Furthermore, the fibrosis of the lung impairs the physiological and biochemical functions of the lung that are independent of the pulmonary gas exchange (oxygen and carbon dioxide) role of the lungs cited above. These include:

(1) filtration, degradation, and removal of the following substances:

- (a) aged leucocytes from the blood, and
- (b) particulate matter (for example, tissue cell debris, blood cell aggregates, inert foreign matter, small thrombi); and

(2) synthesis of adequate supplies of heparin.

[0023] Heparin is a useful substance that normally prevents the formation of life-threatening blood clots in the major

blood vessels (for example, cerebral and coronary blood vessels).

#### C. DIFFERENTIATION BETWEEN ANTI-FIBROTIC ACTIVITY AND ANTI-INFLAMMATORY ACTIVITY

5 [0024] Pharmacological anti-fibrotic activity as exemplified by the arrest and removal of lung scarring (interstitial hyperplasia and fibrotic foci), or pathologic fibrotic lesions in other organs and tissues described herein, is clearly distinct from and independent of any pharmacological anti-inflammatory activity.

10 [0025] The debilitating pathologic degeneration of organs and tissues affected by fibrotic disease continues for extended periods of time, measured in months or years, beyond the short-term (hours and days) of exacerbating inflammatory flare-ups (classical clinical and histopathological signs of edema, local heat, and leucocytic infiltration have disappeared).

15 [0026] The compositions of this invention are effective for treatment of disease caused by the pathologic and excessive fibrotic accumulations such as pulmonary fibrosis, benign prostate hypertrophy, coronary infarcts, cerebral infarcts, myocardial fibrosis, musculoskeletal fibrosis, post-surgical adhesions, liver cirrhosis, renal fibrotic disease, fibrotic vascular disease (atherosclerosis, varix, or varicose veins), scleroderma, Alzheimer's disease, diabetic retinopathy, glaucoma, etc. The pulmonary fibrosis may have been chemically induced, for example, by the anti-cancer drugs bleomycin or cyclophosphamide or by the weed killer paraquat. The compositions of this invention not only arrest the formation of new fibrotic tissue but causes removal of previously formed fibrotic collagen-containing tissue. These pharmacological properties were heretofore unknown.

20 [0027] The present invention arrests formation of or causes removal of a pathogenic accumulation of water-insoluble collagenous connective tissue (for example, excessive scar or lesional fibrotic tissue, etc.). By medicinally removing such pathologic collagenous tissue in fibrotic lungs, the invention eliminates or prevents:

- 25 (1) the mechanical compression or occlusion (stenosis) of blood vessels (for example, pulmonary arteries, veins, and capillaries), pulmonary bronchioles, and alveoli;  
 (2) the inhibition of the primary respiratory function of the alveoli of the lungs, namely, the exchange of oxygen and carbon dioxide gases; and  
 (3) the increased pulmonary blood vessel resistance (cor pulmonale) which readily causes fatal congestive heart failure because of the excessive workload on cardiac muscle that is engendered by the cor pulmonale.

#### D. TREATMENT WITH PIRFENIDONE (Not part of the invention)

30 [0028] As is described in the above-referenced EP-A-0 383 591, the dramatic and novel pulmonary anti-fibrotic activity of pirfenidone has been observed and demonstrated in laboratory animal experiments (rats, hamsters, dogs) and in humans. The anti-fibrotic activity in cardiac infarctions, benign prostatic hypertrophy, and post-operative adhesions has been observed in humans. The renal anti-fibrotic activity has been demonstrated in hamsters. In every instance, the anti-fibrotic activity was clearly distinct from any anti-inflammatory properties.

35 [0029] The acute toxicity of the ingredient in the medical composition of the present invention which exerts the anti-fibrotic activity is as shown in the table below:

ACUTE TOXICITY (LD : mg/kg)				
Route for Administration				
	p.o. (number)	i.v. (number)	i.p. (number)	10% Ointment p.o. (number)
<b>Animal</b>				
<b>Mouse:</b>	<b>997.7(40)</b>	285+/-5(50)	600+/-43(60)	11,500+/-1,100(43)
<b>Rat;</b>				
<b>Male:</b>	<b>1,295(25)</b>		430+/-29(42)	<b>12,500(10)</b>
<b>Female:</b>	<b>2,300(30)</b>			
<b>Guinea Pig:</b>	<b>810+/-25(30)</b>		<b>460+/-28(25)</b>	

(continued)

ACUTE TOXICITY (LD : mg/kg)				
Route for Administration				
	p.o. (number)	i.v. (number)	i.p. (number)	10% Ointment p.o. (number)
<b>Animal</b>				
<b>Rabbit:</b>		280+/-32(12)		
<b>Cat:</b>	500(17)	40(4)		
<b>Dog:</b>	300(11)	200(6)		
<b>Monkey:</b>		100(3)		

[0030] The anti-fibrotic activity measured against pulmonary fibrosis was found to be quite dissimilar to and independent of anti-inflammatory activity when these activities were assayed in rats, mice, hamsters, and rabbits. Experiments in dog and human clinical trials affirm these findings. Pirfenidone has been extensively studied for oral anti-fibrotic activity in laboratory animals and in humans. The anti-fibrotic effect in pulmonary fibrosis was demonstrated upon oral administration:

- 25 (1) in diets or by gavage to rat or hamsters,
- (2) oral capsules in dogs, and
- (3) oral administration to humans.

#### EXAMPLE 1 (not part of the invention)

[0031] The results of a histopathological examination of the lungs of rats for fibrosis (interstitial hyperplasia) after receiving 300mg/kg body weight of pirfenidone in the diet for three months are summarized in Table 2. The individual microscopic readings of the lung are also shown in Table 2, where a score schedule of 0, 1, 2, and 3 reflects the degree of fibrosis.

[0032] The data in Table 2 reveal a statistically significant reduction in the amount of fibrosis in rats receiving pirfenidone as compared to placebo control rats (Group 1). The mean score for the controls (Group 1) was 1.63 +/-0.23, and for Group IV (pirfenidone, 300mg/kg body weight daily was 0.95 +/-0.23.

[0033] Student's T value was 2.43, with P less than 0.02 (highly significant statistically).

[0034] In male and female Beagle dogs, the anti-fibrotic activity was found to be a direct function of the dosage of pirfenidone administered, a classical pharmacological dose-response (Table 3, Figure 1). Lung tissues examined microscopically, and scored on a schedule of 0, 1, 2, and 3 for fibrosis resulted in clear demonstration of statistically significant reduction in pulmonary fibrosis in dogs given the drug as compared to control animals.

[0035] The mean score for Group I (Control) was 2.11 +/-0.31, and for Group IV, which received pirfenidone, 150 mg/kg per day orally in capsules, was 0.22 +/-0.19.

[0036] In hamsters, pulmonary fibrosis induced with cryostile asbestos was removed following oral pirfenidone (Table 4).

[0037] This anti-fibrotic activity was not simply a palliative (relieving) effect.

[0038] The asbestos-induced fibrosis did not recur after the pirfenidone had been discontinued for two months.

[0039] In mice, pulmonary fibrosis induced with cyclophosphamide was removed following oral administration of pirfenidone and an immunosupresant drug in humans and is known to produce pulmonary fibrosis in patients as a side effect.

[0040] A similar experience has been observed in trials on human patients with pulmonary fibrosis caused by asbestos.

[0041] For the first time ever, pirfenidone makes possible a pulmonary resolution process whereby a life-threatening solidified fibrotic lung disease can be restored to a relatively normal tissue where the alveoli are no longer collapsed or occluded. That is, the microscopic examination reveals that the tissues are regenerated and become normal, spongy lungs.

[0042] The novel role of pirfenidone in the therapeutic repair of fibrotic lung tissue featuring removal of fibrotic lesions, and concomitant regeneration of normal lung tissue has been observed in experimental asbestosis by histopathological examination of lung tissue specimens under the light microscope, and electron microscopy (Table 4).

[0043] Very little, if any, fibrotic alterations are seen after treatment with adequate doses of pirfenidone.

[0044] A further novel discovery was the demonstration under the electron microscope that the lung cell-imbedded asbestos fibers which had initiated and maintained the extensive fibrotic lesions also had been removed. This was subsequently confirmed by ashing of lung specimens in a laboratory oven, and then determining the asbestos content.

[0045] The discovery of this additional novel "clearing" property of pirfenidone for the first time affords a therapeutic pharmacological remedy for chronic respiratory disease caused by the inhalation and accumulation in the lungs of harmful foreign matter from polluted air, asbestos, industrial dust (grain, lime, fertilizers, cotton fibers, glass fibers, plastics, coal, etc.), resulting in asbestosis, silicosis, and/or black lung of miners, for example.

TABLE 1

		CONTRAST BETWEEN PROPERTIES OF COLLAGEN AND ELASTIN	
	Property	Collagen	Elastin
1.	Water soluble	-	+
2.	Converts to gelatin on boiling	+	-
3.	Primarily in white connective tissue	+	-
4.	Primarily in yellow connective tissue	-	+
5.	Primarily associated with highly elastic structure (e.g., blood vessels)	-	+
6.	Primarily in organ structural tissue; fibrotic or scar tissue (e.g., lung fibrosis, etc.)	+	-
7.	Metabolic turnover rate	low	high

TABLE 2

GROUP I (CONTROL)					
Animal Number	Sex	Lung Connective Tissue Score			
		0	1	2	3
104	F				x
8	M			x	
72	F	x			
74	F		x		x
75	F		x		x
80	F		x		x
81	F		x		x
82	F	x			
88	F		x		
94	F	x			
1	M	x			
19	M	x			
26	M	x		x	
36	M	x			
43	M		x		
45	M	x			x
52	M	x			
53	M		x		
55	M	x			
	Total:	2	8	4	5
	Mean:	1.63			
	S.E.	0.23			

TABLE 2 (continued)

GROUP IV: PIRFENIDONE, 300 mg/kg (p.o.)						
		Lung Connective Tissue Score				
	Animal Number	Sex	0	1	2	3
5	95	F		x		
10	86	F		x		x
15	93	F	x	x		
20	97	F		x		
25	98	F		x		
30	99	F		x		
35	119	F		x		
40	122	F		x		
45	123	F	x			
50	135	F	x			
55	5	M		x		
60	11	M		x		
65	16	M	x	x		
70	29	M	x			
75	31	M	x			
80	32	M		x		
85	34	M		x		
90	35	M		x		
95	40	M		x		
100		Total:	5	11	2	1
105		Mean:	0.95			
110		S.E.:	0.18			
115		t:	2.43			
120		P:	<0.02			

TABLE 3

Group	Number of Dogs	Hyperplasia Scores*				Average Scores	Incidence of Normal Lung
		0	1	2	3		
I. Control (0.0%)	9	0	3	2	4	2.11+/-0.31	0/9
II. Pirfenidone (16.7%) 25 mg/kg/day	6	1	1	4	0	1.50+/-0.34	1/6
III. Pirfenidone (25.0%) 75 mg/kg/day	8	2	2	3	1	1.38+/-0.38	2/8

\* Degree of Hyperplasia (fibrosis)

0 = normal tissue

1 = minimal

2 = moderate

3 = severe

TABLE 3 (continued)

<b>EFFECT OF ORAL PIRFENIDONE UPON PULMONARY INTERSTITIAL HYPERPLASIA (FIBROSIS) IN DOGS</b>							
<b>Group</b>	<b>Number of Dogs</b>	<b>Hyperplasia Scores*</b>				<b>Average Scores</b>	<b>Incidence of Normal Lung</b>
		<b>0</b>	<b>1</b>	<b>2</b>	<b>3</b>		
<b>IV. Pirfenidone 150 mg/kg/day</b>	<b>9</b>	<b>7</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0.22+-0.15**</b>	<b>7/9</b>

\* Degree of Hyperplasia (fibrosis)

0 = normal tissue

1 = minimal

2 = moderate

3 = severe

\*\* Highly Statistically Significant ( $P<0.001$ )

5

10

15

20

25

30

35

40

45

50

55

**TABLE 4**  
**EFFECT OF ORAL PIRFENIDONE UPON ASBESTOS-INDUCED PULMONARY  
 INTERSTITIAL FIBROSIS IN HAMSTERS**

<u>Group</u>	<u>Animal Number</u>	<u>Lung Density</u>	<u>Pulmonary Fibrosis Score</u>	
			<u>Light Microscope</u>	<u>Electron Microscope</u>
I. Control	1	0.95	0	0
No Asbestos (-);	2	0.90	1	0
No Pirfenidone	3	1.05	1	1
	4	1.10	0	0
Average		1.00+/-0.05	0.50+/-0.25	0.25+/-0.25
II. Asbestos (+);	5	2.70	3	3
No Pirfenidone (-)	6	1.90	2	3
	7	2.53	3	2
	9	2.98	3	3
Average		2.53+/-0.23	2.75+/-0.25	2.75+/-0.25
III. Asbestos (+)*; 10		0.98	0	0
Plus Pirfenidone (+) 12	10	1.04	2	1
	13	1.26	1	0
	14	1.41	1	0
Average		1.17+/-0.10	1.00+/-0.41	0.25+/-0.25

**Student's "T" Values:**

Group II vs. Group III:	5.9**	3.7**	7.1**
Group II vs. Group I:	6.5**	5.9**	7.1**

**Degree of Fibrosis:**

- 0 = normal tissue
- 1 = minimal
- 2 = moderate
- 3 = severe

\* Asbestos by inhalation for 5 days; Pirfenidone, 500 mg/kg/day, orally in the diet for two months, beginning two months after the five-day exposure to asbestos dust.

\*\* Highly Statistically Significant ( $P<0.001$ ).

TABLE 5

EFFECT OF ORAL PIRFENIDONE UPON CYCLOPHOSPHAMIDE-INDUCED INTERSTITIAL FIBROSIS IN MICE				
NO. Mice	Lung Dry Wt. Mg.	Lung OH-Proline MicGm/Lung	Lung OH-Proline MicGm/Mg	Lung FIBROSIS Scores## (N/N)
<b>GROUP I-A (cyclophosphamide only, 200 mg/kg, i.p.)</b>				
10	50.0+/-1.3	313+/-10	6.01+/-24	4.43+/-43 (0/5)
<b>GROUP I-B (cyclophosphamide only, 200 mg/kg, i.p.)</b>				

## Scoring (0 through 6) of lung interstitial hyperplasia and fibrotic nodule formation based on technique recommended by the Pneumoconiosis Committee of the College of American Pathologists, and the National Institute for Occupational Safety and Health (Ref: Arch. Path. Lab. Med., vol. 106, 1982).

TABLE 5 (continued)

<b>EFFECT OF ORAL PIRFENIDONE UPON CYCLOPHOSPHAMIDE-INDUCED INTERSTITIAL FIBROSIS IN MICE</b>				
<b>NO. Mice</b>	<b>Lung Dry Wt. Mg.</b>	<b>Lung OH- Proline MicGm/Lung</b>	<b>Lung OH- Proline MicGm/Mg</b>	<b>Lung FIBROSIS Scores## (N/N)</b>
8	46.8+/-2.3	406+/-21	8.85+/-0.58	3.90+/-0.23 (0/5)
<b>COMBINED GROUPS I-A AND I-B (cyclophosphamide only, 200 mg/kg, i.p.)</b>				
18	48.9+/-1.3	360+/-18	7.50+/-0.44	4.34+/-0.26(0/10)
<b>GROUP II (cyclophosphamide, 200 mg/kg, i.p., plus pirfenidone, 500 mg/kg/day, p.o.)</b>				
10	52.4+/-0.9	284+/-13**	5.46+/-0.31**	2.99+/-0.75(3/5)*
<b>GROUP III (saline control; no cyclophosphamide; no pirfenidone)</b>				
6	45.3+/-1.2	317+/-20	7.00+/-0.42	0.26+/-0.15(5/5)#+
<b>GROUP IV (pirfenidone, 500 mg/kg/day, p.o.; saline; no cyclophosphamide)</b>				
6	39.0+/-2.8**	288+/-9**	7.60+/-0.60	0.68+/-0.35** (5/5)#+

\*\* Differs significantly ( $P <0.01$ ) from Combined Groups I-A and I-B (Student T test for differences between means).

# Differs significantly ( $P <0.05$ ) from Combined Groups I-A and I-B (Chi-square two-fold contingency table; incidence of scores 3.0 or less).

## Scoring (0 through 6) of lung interstitial hyperplasia and fibrotic nodule formation based on technique recommended by the Pneumoconiosis Committee of the College of American Pathologists, and the National Institute for Occupational Safety and Health (Ref: Arch. Path. Lab. Med., vol. 106, 1982).

[0046] Clinical human open trials have been undertaken as follows:

1. Pulmonary fibrosis diagnosed as caused by asbestos was treated with pirfenidone and closely and objectively followed in two subjects. Clinical impressions were dramatic and highly favorable.
2. Pulmonary fibrosis diagnosed as idiopathic in nature was treated with pirfenidone and closely and objectively followed in one subject for over two years. Clinical impressions were highly favorable.
3. Benign prostate hypertrophy in three elderly subjects (66-100 years) was treated with pirfenidone with very good to excellent clinical results. Two subjects suffered from frequency, severe nocturia, incontinence, constant urgency, and in the third these symptoms were less severe. Clinically, all had enlarged prostates that explained the symptoms. The results were dramatic in the eldest subject within two weeks of therapy. Nocturia of 6-7 trips (every 60-90 minutes) per night was reduced to 1 or 2 nightly (4-5 hours apart). In the other two patients, nocturia 3-4 times (every 2-3 hours) was reduced to once nightly 4-5 hours after retiring. In all cases digital examination of the prostate revealed a detectable reduction in the size of the prostate in 3-4 weeks.
4. Fibrosis of the ventricular myocardium, an outcome of repeated coronary infarcts was treated with pirfenidone in one subject (diagnosed as terminal), with objective evidence of the reduction of the fibrosis (electrocardiogram maps and nuclear resonance determinations). The subject lived for an additional three years, despite the fact that the administration of the drug was terminated after 18 months, due to a limited supply.
5. Inhibition of excessive scar formation by direct application of pirfenidone ointment to skin lesions in 10 cases. Mild to moderate skin laceration or lesions failed to generate skin scars, or caused only minimal scarring when pirfenidone ointment was directly applied to the lesion.

[0047] Examples of medical preparations include: (1) capsules, (2) tablets, (3) powders, (4) granules, (5) syrups, (6) injection (intravenous, intramuscular, or drip administration), (7) cream, (8) ointment, (9) inhalation, (10) eye drop, (11) suppositories, (12) pills, etc.

[0048] The above preparations are available. Among them, capsules, injections, cream, and ointments are preferred preparations.

[0049] Preferably, the N-substituted 2-(1H) pyridones according to the invention are administered in an amount of from 25mg to 9600mg per day, more preferably at a level of from 75 mg to 9600 mg per day. Conveniently they can be administered in an amount of from 25 mg to 3200 mg contained in a capsule.

TEST EXAMPLE 1 (No longer part of the invention)

[0050] In one capsule, 800 mg, 1200 mg, or 1600 mg of pirfenidone is contained.

5    TEST EXAMPLE 2 (No longer part of the invention)

[0051] Hydrophilic ointment containing 5 to 10% pirfenidone.

[0052] The average oral dosage for anti-fibrotic activity in humans is 3600 milligrams per day, with a range of from about 2400 milligrams to about 4800 milligrams per day. Administration may be in divided dosage - for example, 1200 milligrams three times per day.

E. COMPOSITIONS AND DOSAGES FOR THE PRESENT INVENTION

[0053] The above-referenced US Patent No. 3,839,346 describes methods of preparation of some N-substituted 2-(1H)-pyridones useful in the present invention. Those pyridones are:

- 15    3-Methyl-1-phenyl-2-(1H) pyridone  
      6-Methyl-1-phenyl-2-(1H) pyridone  
      3,6-Dimethyl-1-phenyl-2-(1H) pyridone  
20    5-Ethyl-1-phenyl-2-(1H) pyridone  
      1-Phenyl-2-(1H) pyridone  
      1,3-Diphenyl-5-methyl-2-(1H) pyridone

[0054] Effective dosages and rates of application of the compositions of the present invention have been found to be effective, or can be expected to be effective, in a range of from about one-quarter to about twice the dosages given above for pirfenidone.

[0055] The compositions of the present invention may be administered in forms consisting of capsules, tablets, powders, granules, syrups, injectable fluids, pills, creams, ointments, inhalable fluids, eye drops, and suppositories.

30    **Claims**

1. The use of a compound selected from 3-methyl-1-phenyl-2-(1H)-pyridone, 6-methyl-1-phenyl-2-(1H) pyridone, 3,6-dimethyl-1-phenyl-2-(1H) pyridone, 5-ethyl-1-phenyl-2-(1H) pyridone, 1-phenyl-2-(1H)-pyridone and 1,3-diphenyl-5-methyl-2-(1H)-pyridone in the preparation of a medicament for the reparation and prevention of fibrotic lesional tissue in a mammal.
2. The use according to claim 1, in which the compound is administered at a dosage from about 5 to 300 mg per kilogram of body weight per day.
3. The use according to claim 1, in which said compound is present in said medicament in an amount from 25 mg to 3200 mg.
4. The use according to claim 3, in which said compound is present in said medicament in an amount from 200 mg to 3200 mg.
5. The use according to any preceding claim, in which said fibrotic lesional tissue is associated with a condition in the group consisting of pulmonary fibrosis, benign prostate hypertrophy, coronary infarcts, cerebral infarcts, myocardial fibrosis, musculoskeletal fibrosis, post-surgical adhesions, liver cirrhosis, renal fibrotic disease, fibrotic vascular disease, scleroderma, Alzheimer's disease, diabetic retinopathy, and skin lesions.
6. The use according to any preceding claim, in which said medicament is in the form of capsules, tablets, powders, granules, syrups, injectable fluids, and pills.
7. The use according to claim 1, in which the medicament is for topical administration and contains said compound in a concentration from 1 to 20% by weight.
8. The use according to claim 7, in which said fibrotic lesional tissue is associated with a condition in the group

consisting of musculoskeletal fibrosis, post-surgical adhesions, scleroderma, glaucoma, and skin lesions.

- 5 9. The use according to claim 7 or claim 8, in which said medicament is in the form of creams, ointments, hydrophilic ointments, inhalable fluids, eye drops, and suppositories.
- 10 10. The use according to any preceding claim, in which the compound is 5-ethyl-1-phenyl-2-(1H) pyridone.

#### Patentansprüche

- 10 1. Verwendung einer unter 3-Methyl-1-phenyl-2-(1H)-pyridon, 6-Methyl-1-phenyl-2-(1H)pyridon, 3,6-Dimethyl-1-phenyl-2-(1H)-pyridon, 5-Ethyl-1-phenyl-2-(1H)-pyridon, 1-Phenyl-2-(1H)-pyridon und 1,3-Diphenyl-5-methyl-2-(1H)-pyridon ausgewählten Verbindung bei der Zubereitung eines Medikamentes zur Reparatur und Vorbeugung fibrotisch geschädigten Gewebes bei einem Säugetier.
- 15 2. Verwendung gemäß Anspruch 1, wobei die Verbindung in einer Dosis von etwa 5 bis 300 mg pro Kilogramm Körpergewicht und Tag verabreicht wird.
- 20 3. Verwendung gemäß Anspruch 1, wobei die besagte Verbindung in dem besagten Medikament in einer Menge von 25 mg bis 3200 mg vorhanden ist.
4. Verwendung gemäß Anspruch 3, wobei die besagte Verbindung in dem besagten Medikament in einer Menge von 200 bis 3200 mg vorhanden ist.
- 25 5. Verwendung gemäß einem der vorherigen Ansprüche, wobei das besagte fibrotisch geschädigte Gewebe mit einem Zustand aus der Gruppe verbunden ist, die aus Lungenfibrose, gutartiger Prostatahypertrophie, Herzinfarkten, Hirninfarkten, myocardialen Fibrosen, Muskel-Skelett-Fibrosen, post-operativen Adhäsionen, Leberzirrhosen, Nieren-Fibroseerkrankungen, fibrotischen Gefäßerkrankungen, Skeleroderma, Alzheimerkrankheit, diabetischer Retinopathie und Hautläsionen besteht.
- 30 6. Verwendung gemäß einem der vorherigen Ansprüche, wobei das besagte Medikament die Form von Kapseln, Tabletten, Pulvern, Granulaten, Sirups, injizierbaren Flüssigkeiten und Pillen hat.
- 35 7. Verwendung gemäß Anspruch 1, wobei das besagte Medikament zur äußerlichen Anwendung ist und die besagte Verbindung in einer Konzentration von 1 bis 20 Gew.-% enthält.
8. Verwendung gemäß Anspruch 7, wobei das besagte fibrotisch geschädigte Gewebe mit einem Zustand aus der Gruppe verbunden ist, die aus Muskel-Skelett-Fibrosen, post-operativen Adhäsionen, Skeleroderma, Glaucom und Hautläsionen besteht.
- 40 9. Verwendung gemäß Anspruch 7 oder 8, wobei das besagte Medikament die Form von Cremes, Salben, hydrophilen Salben, inhalierbaren Fluiden, Augentropfen und Suppositorien hat.
- 45 10. Verwendung gemäß irgendeinem der vorherigen Ansprüche, wobei die Verbindung 5-Ethyl-1-phenyl-2-(1H)-pyridon ist.

#### Revendications

- 50 1. Utilisation d'un composé choisi parmi la 3-méthyl-1-phényl-2-(1H)-pyridone, la 6-méthyl-1-phényl-2-(1H)-pyridone, la 3,6-diméthyl-1-phényl-2-(1H)-pyridone, la 5-éthyl-1-phényl-2-(1H)-pyridone, la 1-phényl-2-(1H)-pyridone et la 1,3-diphényl-5-méthyl-2-(1H)-pyridone dans la préparation d'un médicament destiné à la réparation et à la prévention des lésions tissulaires de type fibrose chez un mammifère.
- 55 2. Utilisation selon la revendication 1, dans laquelle le composé est administré à une dose d'environ 5 à 300 mg par kilogramme de poids corporel par jour.
3. Utilisation selon la revendication 1, dans laquelle ledit composé est présent dans ledit médicament en quantité de

25 mg à 3200 mg.

4. Utilisation selon la revendication 3, dans laquelle ledit composé est présent dans ledit médicament en quantité de 200 mg à 3200 mg.
5. Utilisation selon l'une quelconque des revendications précédente, dans laquelle ladite lésion tissulaire de type fibrose est associée à état pathologique parmi le groupe constitué par les fibroses pulmonaires, l'hypertrophie bénigne de la prostate, l'infarctus coronarien, l'infarctus cérébral, les fibroses myocardiaques, les fibroses musculosquelettiques, les adhérences post-chirurgicales, la cirrhose du foie, les fibroses rénales, les fibroses vasculaires, les sclérodermies, la maladie d'Alzheimer, la rétinopathie diabétique et les lésions de la peau.
10. Utilisation selon l'une quelconque des revendications précédente, dans laquelle ledit médicament est sous la forme de gélules, comprimés, poudres, granulés, sirops, fluides injectables et pilules.
15. Utilisation selon la revendication 1, dans laquelle le médicament est destiné à une administration locale et contient ledit composé à une concentration de 1 à 20% en poids.
20. Utilisation selon la revendication 7, dans laquelle ladite lésion tissulaire de type fibrose est associée à un état pathologique parmi le groupe constitué par les fibroses musculosquelettiques, les adhérences post-chirurgicales, les sclérodermies, les glaucomes et les lésions de la peau.
25. Utilisation selon la revendication 7 ou la revendication 8, dans laquelle ledit médicament est sous la forme de crèmes, de pommades, de pommades hydrophiles, de fluides pour inhalation, de gouttes oculaires et de suppositoires.
10. Utilisation selon l'une quelconque des revendications précédente, dans laquelle le composé est la 5-éthyl-1-phényl-2-(1H)-pyridone.

30

35

40

45

50

55




FIG. 1



EPA/EPO/OEB  
D-80298 München  
+ 49 89 2399-0  
TX 523 656 epmu d  
FAX + 49 89 2399-4465

Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

Generaldirektion 2

Directorate General 2

Direction Générale 2

Harrison, Ivor Stanley  
Withers & Rogers,  
Goldings House, 2 Hays Lane  
London SE1 2HW  
GRANDE BRETAGNE



Datum/Date

22.04.02

Zeichen/Ref/Réf. <b>F5086/ISH/MDS</b>	Anmeldung Nr./Application No./Demande n°./Patent Nr./Patent No./Brevet n°. <b>94916710.0-2107/US9405156</b>
Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire <b>MARGOLIN, Solomon B.</b>	

#### COMMUNICATION UNDER RULE 51(6) EPC

Further to the communication under Rule 51(4) dated 02.01.02

your approval of the text to be used as the basis for grant has been  
duly received.

Insofar as you have not already fulfilled the requirements mentioned below, you are now requested within a non-extendable period of three months from notification of this communication

1. to file in duplicate translations of the claim(s) in the two other EPO official languages;  
EUR
- 2a. to pay the fee for grant including the fee for printing up to and including 35 pages;  
Reference 007 ..... 715.00
- 2b. to pay the printing fee for the 36th and each additional page; Number of pages: 0  
Reference 008 ..... 0.00
3. to pay the additional claims fee(s)  
(Rule 51(7) EPC);  
Number of claims fees payable: 0  
Reference 016 ..... 0.00  
-----  
Total amount ..... 715.00



For all payments you are requested to use EPO Form 1010 or to refer to the relevant reference number.

If additional copies of the patent specification are required, you should request this in writing and quote Fee reference code 058 when making payment.

If the grant, printing or claims fees are not paid or the translations not filed in due time, the European patent application will be deemed to be withdrawn (Rule 51(8) EPC).

**Note on payment of renewal fees**

-----

If a renewal fee falls due between notification of the present communication and the proposed date of publication of the mention of the grant of the European patent, publication will be effected only after the renewal fee and any additional fee has been paid (Rule 51(9) EPC).

Under article 86(4) EPC, renewal fees are payable to the European Patent Office until the year in which the mention of the grant of the European patent is published.

**Filing of translations in the Contracting States**

-----

Pursuant to Article 65(1) EPC the following designated Contracting States require a translation of the specification of the European patent in their/one of their official language(s) (Rule 51(10) EPC), insofar this specification will not be published in their/one of their official language(s)

- within three months of publication of the mention of such decision:

AT AUSTRIA  
BE BELGIUM  
CH SWITZERLAND/LIECHTENSTEIN  
DE GERMANY  
DK DENMARK  
ES SPAIN  
FR FRANCE  
GB UNITED KINGDOM  
GR GREECE  
IT ITALY  
NL NETHERLANDS  
PT PORTUGAL  
SE SWEDEN

- within six months of publication of the mention of such decision:



## IE IRELAND

The date on which the European Patent Bulletin publishes the mention of the grant of the European patent will be indicated in the decision on the grant of the European patent (EPO Form 2006).

## In case of a valid extension

the following Extension States require a translation of the CLAIMS in their official language within three months after publication of the mention of the grant of the European patent:

AL ALBANIA

LT LITHUANIA

LV LATVIA

MK MACEDONIA

RO ROMANIA (requires translation of the specification)

SI SLOVENIA

The translation must be filed with the national Patent Offices of the Contracting or Extension States in accordance with the provisions applying thereto in the State concerned. Further details (e. g. appointment of a national representative or indication of an address for service within the country) are given in the EPO information brochure "National law relating to the EPC", and in the supplementary information published in the Official of the EPO.

Failure to supply such translation to the Contracting and Extension States in time and in accordance with the requirements may result in the patent being deemed to be void ab initio in the State concerned.

Note to users of the automatic debiting procedure:  
-----

Unless the EPO receives prior instructions to the contrary, the fee(s) will be debited on the last day of the period for payment. For further details see the Arrangements for the automatic debiting procedure (see Supplement to OJ EPO 2/1999; OJ EPO 2000, 62).

## For the Examining Division:

HUNDT D

Tel. No.: (+49-89) 2399-8042

NB: If a translation of the previous application (Rule 38(5) and 51(6) EPC) is still missing, Form 2530 is dispatched separately.





✉ EPA/EPO/OEB  
D-80298 München  
☎ +49 89 2399-0  
TX 523 656 epmu d  
FAX +49 89 2399-4465

Europäisches  
Patentamt

Generaldirektion 2

European  
Patent Office

Directorate General 2

Office européen  
des brevets

Direction Générale 2

Harrison, Ivor Stanley  
Withers & Rogers,  
Goldings House, 2 Hays Lane  
London SE1 2HW  
GRANDE BRETAGNE



Application No. 94 916 710.0-2107	Ref. F5086/ISH/MDS	Date 02.01.2002
Applicant MARGOLIN, Solomon B.		

#### Communication under Rule 51(4) EPC

You are hereby informed that the Examining Division intends to grant a European patent on the basis of the above application with the text and drawings as indicated below:

##### Text for the Contracting States:

AT BE CH LI DE DK ES FR GB GR IE IT LU NL PT SE

##### Description, pages:

4-6,8,12-15,19,      as originally filed  
21-23

9-11,16-18,20      as received on      05.12.1995      with letter of      30.11.1995

1-3,7      as received on      24.10.2001      with letter of      19.10.2201

##### Claims, No.:

1-10      as received on      04.04.2001      with letter of      30.03.2001

##### Drawings, sheets:

1/1      as originally filed

#### With the following amendments to the above-mentioned documents by the division:

Description, pages:      7,10,20-23\*

##### Comments:

\* Adaptation description to claims



Date

02.01.2002

Sheet 2

Application-No.: 94 916 710.0

See also comments on enclosed Form 2906.

A copy of the relevant documents is enclosed.

The title of the invention in the three official languages of the European Patent Office, the international patent classification, the designated Contracting States and the registered name of the applicant are shown on the attached EPO Form 2056.

You are requested to state your approval of the text specified above **within four months** of this notification. Failure to do so will result in refusal of the application under Article 97(1) EPC, except as provided by Rule 51(5) EPC, second sentence.

The filing of a divisional application is only possible up to the approval of the text specified above (Rule 25(1) EPC).

Concerning the possibility of a request for accelerated grant pursuant to Article 97(6) EPC, reference is made to OJ EPO 1997, 340.

Further information concerning the acceptability of amendments or the filing of a separate set of claims for one or more designated Contracting States that have entered a reservation under Article 167(2)a) EPC will be found in the Guidelines for Examination in the EPO, C-VI, 4.8 - 4.10 and C-VI, 15.1.2 - 15.1.4.

If the translation of the priority document(s), as required by Article 88(1) EPC, or the declaration according to Rule 38(5) EPC has not yet been filed, it is to be filed within the time limit mentioned in Rule 38(5) EPC at the latest.

**Examining Division:**

**Chairman:** CATTELL R J  
**2nd Examiner:** GIACOBBE S A  
**1st Examiner:** LAFFARGUE-HAAK T



Hundt, D  
**For the Examining Division**  
Tel. No.: +49 89 2399-8042

Enclosure(s): Form 2906  
Form 2056  
26 Copies of the relevant documents

-1-

Description

Compositions and Methods For Reparation  
And Prevention of Fibrotic Lesions

5

Technical Field of the Invention

The present invention relates to medical compositions and methods for the reparation of fibrotic lesional tissues and the prevention of fibrotic lesions, which compositions 10 comprise one or more N-substituted 2(1H) pyridones and/or one or more N-substituted 3(1H) pyridones as active anti-fibrotic ingredient(s).

Background Art

15 Herein, the term "anti-fibro", "anti-fibrotic" or "anti-fibrosis" refers to the reparations and/or prevention of pathological polymerization of collagen in lung fibrosis, arteriosclerosis, prostatic hypertrophy, keloid, myocarditis, collagen disease, scar, wrinkle, etc., and 20 reparation as well normalization of the existing pathological fibrotic tissues.

Methods of preparation of some N-substituted 2(1-H) pyridones useful in the present invention are described in US Patent No. 3,839,346, issued October 1, 1974, to Gadekar, 25 and titled N-SUBSTITUTED PYRIDONE AND GENERAL METHOD FOR PREPARING PYRIDONES, the disclosure of which is incorporated by reference hereinto. That patent also describes use of those compounds in analgesic, anti-inflammatory, and anti-pyretic treatments. US Patents Nos. 3,974,281, issued 30 August 10, 1976; 4,042,699, issued August 16, 1977; and 4,052,509, issued October 4, 1977, all to Gadekar, describe further use of one of these compounds, 5-methyl-1-phenyl-2-(1H) pyridone ("pirfenidone"), in lowering serum uric acid and glucose levels, treating upper respiratory inflammatory 35 conditions, and treating inflammatory skin conditions, in humans and other mammals.

The use of pirfenidone in the reparation and prevention of fibrotic lesions is described in the above EP-A-0383591.

-2-

~~filed September 21, 1992, the disclosure of which is  
incorporated by reference hereinto.~~

It has been discovered by the present inventor that other N-substituted 2(1H) pyridone compounds and N-  
5 substituted 3(1H) pyridone compounds also have anti-fibrotic activity. Heretofore, before the discoveries of the inventions disclosed herein and in the above copending applications, no effective pharmacological agent or composition has been available for the prevention or removal  
10 of pathologic fibrotic lesions of the lungs, prostate glands, musculoskeletal diseases, myocardial degeneration, myocardial infarction, arteriosclerosis, and other lesional fibroses.

For example, powerful anti-inflammatory  
15 glucocorticoids (hormones relating to carbohydrate metabolism) such as hydrocortisone or prednisolone administered in very large doses have repeatedly been shown to be ineffective against fibrotic disease. These glucocorticoids do not arrest or remove such life-  
20 threatening fibrotic lesions. The glucocorticoids may be effective, however, as anti-inflammatory agents under such condition that they may temporarily ameliorate the secondary acute inflammation flare-ups which intermittently occur in tissues or organs damaged by fibrotic disease. Indeed,  
25 excessive and prolonged administration of glucocorticoids in pulmonary fibrotic disease may cause destruction of tissues, due to fibrosis or an exacerbation and acceleration of the fibrotic destruction.

Antopol (1950) was the first of many investigators who  
30 found that the anti-inflammatory glucocorticoids readily enhance fibrotic degeneration of lung tissues. Similarly, the non-steroidal anti-inflammatory agents such as aspirin, salicylates, phenylbutazone, indomethacin, various phenylacetic acid derivatives, and the like have also failed  
35 to arrest formation of, or cause repair of progressive, chronic fibrotic damage to lung tissues; prostatic tissues, musculoskeletal tissues, etc.

Accordingly, it is a principal object of the present invention to provide compositions for the reparation and prevention of fibrotic lesional tissue.

It is an additional object of the invention to provide such compositions that comprise one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s) as active anti-fibrotic ingredient(s).

Other objects of the present invention, as well as particular features and advantages thereof, will be elucidated in, or be apparent from, the following description.

#### Disclosure of Invention

The present invention provides the use of a compound selected from 3-methyl-1-phenyl-2-(1H)-pyridone, 6-methyl-1-phenyl-2-(1H) pyridone, 3,6-dimethyl-1-phenyl-2-(1H) pyridone, 5-ethyl-1-phenyl-2-(1H) pyridone, 1-phenyl-2-(1H)-pyridone and 1,3-diphenyl-5-methyl-2-(1H)-pyridone in the preparation of a medicament for the reparation and prevention of fibrotic lesional tissue in a mammal.

#### Best Mode for Carrying Out the Invention

The "anti-fibrotic" activity described herein differs from "fibrinolytic" or "anti-fibrin" activity. The fibrinolytic" or "anti-fibrin" activity refers to the biological ability of a pharmaceutical substance to (1) prevent fibrin formation (prevent formation of a blood clot) or (2) lyse or dissolve a previously formed blood clot.

The "anti-fibrotic" activity discovered by the present inventor and as used herein refers to the ability of an active substance to (1) prevent an excessive pathologic accumulation of collagenous scar or connective tissue in

-7-

adhesions, liver cirrhosis, real fibrotic disease, fibrotic vascular disease (atherosclerosis, varix, or varicose veins), scleroderma, Alzheimer's disease, diabetic retinopathy, glaucoma, etc. The pulmonary fibrosis may have been chemically induced, for example, by the anti-cancer drugs bleomycin or cyclophosphamide or by the weed killer paraquat. The compositions of this invention not only arrest the formation of new fibrotic tissue but causes removal of previously formed fibrotic collagen-containing tissue. These pharmacological properties were heretofore unknown.

The present invention arrests formation of or causes removal of a pathogenic accumulation of water-insoluble collagenous connective tissue (for example, excessive scar or lesional fibrotic tissue, etc.). By medicinally removing such pathologic collagenous tissue in fibrotic lungs, the invention eliminates or prevents:

- (1) the mechanical compression or occlusion (stenosis) of blood vessels (for example, pulmonary arteries, veins, and capillaries), pulmonary bronchioles, and alveoli;
- (2) the inhibition of the primary respiratory function of the alveoli of the lungs, namely, the exchange of oxygen and carbon dioxide gases; and
- (3) the increased pulmonary blood vessel resistance (cor pulmonale) which readily causes fatal congestive heart failure because of the excessive workload on cardiac muscle that is engendered by the cor pulmonale.

30 **D. TREATMENT WITH PIRFENIDONE**

EP-A-0383591,

As is described in the above-referenced US Application No. 07/947,995, the dramatic and novel pulmonary anti-fibrotic activity of pirfenidone has been observed and demonstrated in laboratory animal experiments (rats, hamsters, dogs) and in humans. The anti-fibrotic activity in cardiac infarctions, benign prostatic hypertrophy, and post-operative adhesions has been observed in humans. The renal anti-fibrotic activity has been demonstrated in

**WITHERS◆ROGERS****EUROPEAN & CHARTERED PATENT ATTORNEYS  
TRADE MARK ATTORNEYS**

Goldings House, 2 Hays Lane, London SE1 2HW

Tel: +44 (0)20 7663 3500 Fax: +44 (0)20 7663 3550

E-Mail: admin@withersrogers.com Web: www.withersrogers.com

European Patent Office  
D-80298  
München  
Germany

Our Ref: P102063EP-PCT/ISH/EC  
Your Ref:

19 October 2001  
BY FACSIMILE  
(CONFIRMATION BY POST)

Dear Sirs

**European Application No. 94916710.0  
Solomon B Margolin**

We refer to the official letter dated 26th September 2001 in the above application and, although it is considered that the reasoning advanced for rejecting the disclaimer does not address, or even refer to, the arguments advanced in our letter dated 30th March 2001, nevertheless we hereby withdraw the applicant's request for oral proceedings and request that a Communication under Rule 51(4) EPC be issued on the basis of the auxiliary request.

We enclose triplicate copies of replacement pages 1, 2, 3 and 7 of the description in which references to "disclosure of which is incorporated by reference" have been deleted, a reference to prior art document D1 has been substituted for the "co-pending US application Serial No. 07/947,995" on pages 1 and 7 and a statement of invention commensurate with claim 1 of the auxiliary request has been provided at page 3.

With particular reference to D1 and the US application, the representative does not know whether the US application was ever published or, indeed, whether it is equivalent to D1 but the subject matter of the US application as referred to in the description appears to be commensurate with D1 and it is therefore believed that this amendment will meet the requirement as set out in the official letter dated 29th November 2000.

cont....

Re: 9(2001)

**Partners:** David Bannerman, Nicholas Wilson, Michael Blatchford, Adrian Chettle, Jeff Hogg, John Dean, Ben Dempster, Karl Barnfather, Simon Beck, Ivor Harrison, David Pratt, Mark Armitage\*, Colin Jones, Howard Wright, David Croston, Nigel Parcell\*, Andrew Murch\*, John Jones  
**Consultant Partner:** Peter Turner

\* MITMA. All other partners C.P.A. & E.P.A.

**Associates:** Christopher Hey, Fiona McBride, David Elsy, Adrian Tombling, James Gray, Paul Derry, Jackie Tolson, Joecta Murphy, David Fry, Alex Duftield, Matthew Allen, Keith Tait, Laurel McBray, Callum Wardle, Robert Sayer, Matthew Gillard, Paul Foot, Christopher Hamer, Nicholas Jones, Helen Cawley

**Consultants:** Michael Adkins, David Cowan

**Administration:** Sally Cooper, **Accounts:** Mary Sturgess, **Renewals:** David Ayres (Manager), Mary Downey

**Translations:** Rosemary Booth, **Searchline:** Robin Webster, **EP Formalities:** Karen Auster

**WITHERS◆ROGERS**


European Patent Office

19 October 2001

Page 2

The Examiner is invited to contact the undersigned by telephone should any matters remain outstanding but it is believed that the application is now in condition for grant and we await receipt of the Communication under Rule 51(4) EPC.

Yours faithfully



I S Harrison  
WITHERS & ROGERS

Enc.

-1-

Description

Compositions and Methods For Reparation  
And Prevention of Fibrotic Lesions

5

Technical Field of the Invention

The present invention relates to medical compositions and methods for the reparation of fibrotic lesional tissues and the prevention of fibrotic lesions, which compositions 10 comprise one or more N-substituted 2(1H) pyridones and/or one or more N-substituted 3(1H) pyridones as active anti-fibrotic ingredient(s).

Background Art

15 Herein, the term "anti-fibro", "anti-fibrotic" or "anti-fibrosis" refers to the reparations and/or prevention of pathological polymerization of collagen in lung fibrosis, arteriosclerosis, prostatic hypertrophy, keloid, myocarditis, collagen disease, scar, wrinkle, etc., and 20 reparation as well normalization of the existing pathological fibrotic tissues.

Methods of preparation of some N-substituted 2(1-H) pyridones useful in the present invention are described in US Patent No. 3,839,346, issued October 1, 1974, to Gadekar, 25 and titled N-SUBSTITUTED PYRIDONE AND GENERAL METHOD FOR PREPARING PYRIDONES, the disclosure of which is incorporated by reference hereinto. That patent also describes use of those compounds in analgesic, anti-inflammatory, and anti-pyretic treatments. US Patents Nos. 3,974,281, issued August 10, 1976; 4,042,699, issued August 16, 1977; and 30 4,052,509, issued October 4, 1977, all to Gadekar, describe further use of one of these compounds, 5-methyl-1-phenyl-2-(1H) pyridone ("pirfenidone"), in lowering serum uric acid and glucose levels, treating upper respiratory inflammatory 35 conditions, and treating inflammatory skin conditions, in humans and other mammals.

The use of pirfenidone in the reparation and

EP-A-0383591.

-2-

~~filed September 21, 1991, the disclosure of which is incorporated by reference hereinto.~~

It has been discovered by the present inventor that other N-substituted 2(1H) pyridone compounds and N-substituted 3(1H) pyridone compounds also have anti-fibrotic activity. Heretofore, before the discoveries of the inventions disclosed herein and in the above copending applications, no effective pharmacological agent or composition has been available for the prevention or removal of pathologic fibrotic lesions of the lungs, prostate glands, musculoskeletal diseases, myocardial degeneration, myocardial infarction, arteriosclerosis, and other lesional fibroses.

For example, powerful anti-inflammatory glucocorticoids (hormones relating to carbohydrate metabolism) such as hydrocortisone or prednisolone administered in very large doses have repeatedly been shown to be ineffective against fibrotic disease. These glucocorticoids do not arrest or remove such life-threatening fibrotic lesions. The glucocorticoids may be effective, however, as anti-inflammatory agents under such condition that they may temporarily ameliorate the secondary acute inflammation flare-ups which intermittently occur in tissues or organs damaged by fibrotic disease. Indeed, excessive and prolonged administration of glucocorticoids in pulmonary fibrotic disease may cause destruction of tissues, due to fibrosis or an exacerbation and acceleration of the fibrotic destruction.

Antopol (1950) was the first of many investigators who found that the anti-inflammatory glucocorticoids readily enhance fibrotic degeneration of lung tissues. Similarly, the non-steroidal anti-inflammatory agents such as aspirin, salicylates, phenylbutazone, indomethacin, various phenylacetic acid derivatives, and the like have also failed to arrest formation of, or cause repair of progressive, chronic fibrotic damage to lung tissues; prostatic tissues, musculoskeletal tissues, etc.

Accordingly, it is a principal object of the present invention to provide compositions for the reparation and prevention of fibrotic lesional tissue.

It is an additional object of the invention to provide such compositions that comprise one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s) as active anti-fibrotic ingredient(s).

Other objects of the present invention, as well as particular features and advantages thereof, will be elucidated in, or be apparent from, the following description.

#### Disclosure of Invention

The present invention provides the use of a compound selected from 3-methyl-1-phenyl-2-(1H)-pyridone, 6-methyl-1-phenyl-2-(1H) pyridone, 3,6-dimethyl-1-phenyl-2-(1H) pyridone, 5-ethyl-1-phenyl-2-(1H) pyridone, 1-phenyl-2-(1H)-pyridone and 1,3-diphenyl-5-methyl-2-(1H)-pyridone in the preparation of a medicament for the reparation and prevention of fibrotic lesional tissue in a mammal.

#### Best Mode for Carrying Out the Invention

The "anti-fibrotic" activity described herein differs from "fibrinolytic" or "anti-fibrin" activity. The fibrinolytic" or "anti-fibrin" activity refers to the biological ability of a pharmaceutical substance to (1) prevent fibrin formation (prevent formation of a blood clot) or (2) lyse or dissolve a previously formed blood clot.

The "anti-fibrotic" activity discovered by the present inventor and as used herein refers to the ability of an active substance to (1) prevent an excessive pathologic accumulation of collagenous scar or connective tissue in

-7-

adhesions, liver cirrhosis, real fibrotic disease, fibrotic vascular disease (atherosclerosis, varix, or varicose veins), scleroderma, Alzheimer's disease, diabetic retinopathy, glaucoma, etc. The pulmonary fibrosis may have been chemically induced, for example, by the anti-cancer drugs bleomycin or cyclophosphamide or by the weed killer paraquat. The compositions of this invention not only arrest the formation of new fibrotic tissue but causes removal of previously formed fibrotic collagen-containing tissue. These pharmacological properties were heretofore unknown.

The present invention arrests formation of or causes removal of a pathogenic accumulation of water-insoluble collagenous connective tissue (for example, excessive scar or lesional fibrotic tissue, etc.). By medicinally removing such pathologic collagenous tissue in fibrotic lungs, the invention eliminates or prevents:

- (1) the mechanical compression or occlusion (stenosis) of blood vessels (for example, pulmonary arteries, veins, and capillaries), pulmonary bronchioles, and alveoli;
- (2) the inhibition of the primary respiratory function of the alveoli of the lungs, namely, the exchange of oxygen and carbon dioxide gases; and
- (3) the increased pulmonary blood vessel resistance (cor pulmonale) which readily causes fatal congestive heart failure because of the excessive workload on cardiac muscle that is engendered by the cor pulmonale.

30 D. TREATMENT WITH PIRFENIDONE

EP-A-0383591,

As is described in the above-referenced US Application No. 07/947,995, the dramatic and novel pulmonary anti-fibrotic activity of pirfenidone has been observed and demonstrated in laboratory animal experiments (rats, hamsters, dogs) and in humans. The anti-fibrotic activity in cardiac infarctions, benign prostatic hypertrophy, and post-operative adhesions has been observed in humans. The

# WITHERS & ROGERS

EUROPEAN & CHARTERED PATENT ATTORNEYS  
TRADE MARK ATTORNEYS

1 Redcliff Street, Bristol BS1 6NP

Tel: +44 (0)117 925 3030 Fax: +44 (0)117 925 3530

E-Mail: admin@withersrogers.com Web: www.withersrogers.com

By Fax Only

## FAX MESSAGE

To:

COMPANY: European Patent Office - Munich

FAX NO: 0049 89 2399 4465

YOUR REF:

SUBJECT: European Patent Application No. 94916710.0

NO. OF PAGES (INCLUDING COVER): 7

FROM: John Dean

DATE: 19 October 2001

OUR REF: P102063EP-PCT/JPD/EC

**Message:** Please see attached letter.

This facsimile is intended for the addressee only, and may contain confidential or privileged information. If you are not the named addressee, please notify us immediately by return facsimile or telephone; do not distribute, copy or disclose the contents of this facsimile to anyone else.

**PLEASE LET US KNOW IN THE EVENT OF POOR TRANSMISSION, OR IF  
YOU DO NOT RECEIVE ALL PAGES**

A list of Partners may be inspected at the above address



✉ EPA/EPO/OEB  
D-80298 München  
☎ +49 89 2399-0  
TX 523 656 epmu d  
FAX +49 89 2399-4465

**Europäisches  
Patentamt**

Generaldirektion 2

**European  
Patent Office**

Directorate General 2

**Office européen  
des brevets**

Direction Générale 2

Harrison, Ivor Stanley  
Withers & Rogers,  
Goldings House, 2 Hays Lane  
London SE1 2HW  
GRANDE BRETAGNE

**Telephone Numbers:**

**Primary Examiner** +49 89 2399-8009  
(substantive examination)

**Formalities Officer / Assistant** +49 89 2399-8042  
(Formalities and other matters)



Application No. 94 916 710.0-2107	Ref. F5086/ISH/MDS	Date 26.09.2001
Applicant MARGOLIN, Solomon B.		

**Invitation pursuant to Article 96(2) and Rule 51(2) EPC**

Further examination of the above application has revealed that, for the reasons given in the enclosed copy of the result of consultation by telephone on 18.09.2001, it does not meet the requirements of the European Patent Convention.

You are requested to remedy the indicated deficiencies within a

**period of 1 months**

from notification of this invitation.

The time limit is calculated in accordance with the provisions of Rule 78(2), 83(2) and (4) EPC.

Failure to reply to this invitation in due time will result in the European application being deemed to be withdrawn (Article 96(3) EPC).



LAFFARGUE-HAAK T  
For the Examining Division

Enclosure(s): Copy of result of consultation (Form 2036)

**WITHERS ROGERS**  
EUROPEAN & CHARTERED PATENT ATTORNEYS  
TRADE MARK ATTORNEYS

Goldings House, 2 Hays Lane, London SE1 2HW  
Tel: +44 (0)20 7663 3500 Fax: +44 (0)20 7663 3550  
E-Mail: admin@withersrogers.com Web: www.withersrogers.com

European Patent Office  
D-80298  
München  
Germany

Our Ref:  
P102063EP-PCT/ISH/NAJ  
Your Ref:

30 March 2001

To Contact the Writer: Telephone: +44 117 925 3030

**BY FAX**

Dear Sirs

**European Application No 94916710.0-2107 based on PCT/US94/05156**  
**"Composition and methods for reparation and prevention of fibrotic lesions"**  
**Solomon B Margolin**

I refer to the examination report dated 29th November 2000 in the above application and request that examination be continued on the basis of the claims as currently held on file. If, despite the argument below, the Examiner still finds these claims objectionable for the reasons given in his current report, it is requested that examination be based on the replacement set of claims enclosed in triplicate with this response. These replacement claims are marked 'Auxiliary Set' and form new pages 24 and 25. In the event that the auxiliary set of claims come to be examined, existing pages bearing these numbers are hereby withdrawn without prejudice to their possible reinstatement at a later date.

The Examiner has stated that the disclaimer in current claim 1 leads to a Contravention of Art 123(2) EPC because the prior art document D1, on which the disclaimer has been said to be based, is still relevant for examination of the claims even once the disclaimer is made. Two EPO decisions, T0596/96 and T0863/96, have been referred to in support of this statement.

Having studied the above decisions, we are of the opinion that they are not relevant in the present case. These decisions are concerned with the situation where a disclaimer is not supported by the application as filed and hence can only be an amendment allowable under Art 123(2) EPC if the 'disclaimer criteria' are met. Thus, in T0596/96, it is said (at 2.1) that 'from the language of this part of the application [the description of the prior art], seen in relation to the actual description of the invention, the skilled reader could not deduce directly and unambiguously that the invention (sic) as filed was intended to exclude the methods which are now the object of the disclaimer'. In the application in suit, on the other hand, there is basis, it is submitted, in the application as filed for the specific exclusion of the use of pirfenidone from the ambit of the claims. The paragraph bridging original pages 1 and 2 clearly identifies the prior use of pirfenidone in the treatment of fibroses. The next paragraph, in framing the present invention, explains lucidly that the contribution to the art for which a patent is now being sought is the provision of 'other... compounds [than

Ref 7/2000

C/Lester

Partners: David Bannerman, Nicholas Wilson, Michael Blatchford, Michael Adkins, Adrian Chettle, Jeff Hogg, John Dean, Ben Dempster, Karl Barnfather, Ivor Harrison, David Pratt, Mark Armitage\*, Simon Beck, Colin Jones, Howard Wright, David Croston Consultant Partner: Peter Turner  
*All partners are C.P.A. & E.P.A. unless indicated\**

Associates: Christopher Hey, Nigel Parnell, Andrew Murch, John Jones, David Elsy, David Fry, James Gray, Alex Duffield, Paul Derry, Matthew Allen, Keith Turt, Laurel McBray, Robert Sayer

Practice Manager: Richard Clark, Accounts: Mary Sturgess, Renewals: David Ayres (Manager), Mary Downey, Administration: Susan Savage, Translations: Rosemary Booth, Searching: Robin Webster, EP Formalities: Karen Austen

Also at 60 Holly Walk, Leamington Spa, Warwickshire CV32 4TR Tel: +44 (0)1926 224111 Fax: +44 (0)1926 224410

# WITHERS◆ROGERS

Page 2


pirfenidone] ... also [having] anti-fibrotic activity.<sup>7</sup> In addition, pirfenidone is conspicuously absent from the list of pyridones 'useful in the present invention' given on pages 21 and 22.

It is therefore submitted that the addition of a disclaimer to claim 1 does not cause the application to contain any matter that the skilled person could not have derived clearly and unambiguously from the application as filed. Because of this, no further criteria have to be met by this disclaimer and it should not be viewed as any sort of exceptional means for reinstalling novelty to the present claims.

If the Examiner still finds the present claims unacceptable, then it is requested that the next official letter be based on the auxiliary set of claims enclosed with this response. The Examiner has indicated that claims 10 and 11 as currently on file are acceptable. Therefore, in the auxiliary set, claim 10 has been amended to become new independent claim 1, current claims 2 to 9 remain in their present form (although they obviously now depend on the 'claim 10 subject matter') and new claim 10 corresponds with current claim 11.

It is requested that amendment of the description be deferred pending acceptance of either the current or the auxiliary set of claims. In order to expedite the remaining stages of the prosecution of this application, we would be grateful if the decision on claim acceptance could be communicated to the undersigned by telephone in the first instance, following which we will be able to prepare and file the appropriately amended pages of the description without undue delay. In any event, oral proceedings are hereby requested as a precautionary measure.

Yours faithfully



I S Harrison  
WITHERS & ROGERS

Encs:

# WITHERS® ROGERS

EUROPEAN &amp; CHARTERED PATENT ATTORNEYS

1 Redcliff Street, Bristol BS1 6NP

Tel: +44 (0)117 925 3030 Fax: +44 (0)117 925 3530

E-Mail: admin@withersrogers.com Web: www.withersrogers.com

DX: 78234 Bristol

## Confirmation Copy to Follow

## FAX MESSAGE

To:

COMPANY: European Patent Office - Munich

FAX NO: 0049 89 2399 4465

YOUR REF:

SUBJECT: European Patent Application No. 94916710.0-2107

No. OF PAGES (INCLUDING COVER): 5

FROM: Ivor Harrison

DATE: 30 March 2001

OUR REF: P102063EP-PCT/ISH/EC

**Message:** Please see attached.

This facsimile is intended for the addressee only, and may contain confidential or privileged information. If you are not the named addressee, please notify us immediately by return facsimile or telephone; do not distribute, copy or disclose the contents of this facsimile to anyone else.

**PLEASE LET US KNOW IN THE EVENT OF POOR TRANSMISSION, OR IF  
YOU DO NOT RECEIVE ALL PAGES**

A list of Partners may be inspected at the above address



EPA/EPO/OEB  
D-80298 München  
 +49 89 2399-0  
 TX 523 656 epmu d  
 FAX +49 89 2399-4465

**Europäisches  
Patentamt**

Generaldirektion 2

**European  
Patent Office**

Directorate General 2

**Office européen  
des brevets**

Direction Générale 2

Harrison, Ivor Stanley  
Withers & Rogers,  
Goldings House, 2 Hays Lane  
London SE1 2HW  
GRANDE BRETAGNE

**Telephone Numbers:**

**Primary Examiner** +49 89 2399-8009  
(substantive examination)

**Formalities Officer / Assistant** +49 89 2399-8071  
(Formalities and other matters)



Application No. 94 916 710.0-2107	Ref. F5086/ISH/MDS	Date 29.11.2000
Applicant MARGOLIN, Solomon B.		

**Communication pursuant to Article 96(2) EPC**

The examination of the above-identified application has revealed that it does not meet the requirements of the European Patent Convention for the reasons enclosed herewith. If the deficiencies indicated are not rectified the application may be refused pursuant to Article 97(1) EPC.

You are invited to file your observations and insofar as the deficiencies are such as to be rectifiable, to correct the indicated deficiencies within a period

**of      4      months**

from the notification of this communication, this period being computed in accordance with Rules 78(2) and 83(2) and (4) EPC.

Amendments to the description, claims and drawings are to be filed where appropriate within the said period in **three copies** on separate sheets (Rule 36(1) EPC).

**Failure to comply with this invitation in due time will result in the application being deemed to be withdrawn (Article 96(3) EPC).**



LAFFARGUE-HAAK T  
Primary Examiner  
for the Examining Division

Enclosure(s): 2 page/s reasons (Form 2906)



Bescheid/Protokoll (Anlage)		Communication/Minutes (Annex)		Notification/Procès-verbal (Annexe)	
Datum Date Date	29.11.2000	Blatt Sheet Feuille	1	Anmelde-Nr.: Application No.: Demande n°:	94 916 710.0

The examination is being carried out on the **following application documents**:

Text for the Contracting States:

AT BE CH LI DE DK ES FR GB GR IE IT LU NL PT SE

**Description, pages:**

1-8,12-15,19, as originally filed  
21-23

9-11,16-18,20 as received on 05.12.1995 with letter of 30.11.1995

**Claims, No.:**

1-11 as received on 23.05.2000 with letter of 18.05.2000

**Drawings, sheets:**

1/1 as originally filed

**1. Unallowable disclaimer**

The Examining Division has reconsidered the disclaimer in independent claim 1 and it is of the opinion that the present claims contravene Art. 123(2) EPC, because the cited prior art document D1 is still relevant for further examination of the claimed invention (T 0596/96 and T 0863/96). In addition, the Examining Division notes that this document can certainly not be considered as an *accidental* novelty-destroying disclosure as the patentee of D1 and the applicant of the present application are the same natural person.

**2. Patentability of claims 10 and 11**

The Examining Division is of the opinion that the subject-matter of present claims 10 and 11 meets the requirements of the EPC. These claims are novel and inventive over D1, considered as the closest prior art. The technical problem would be to provide improved compositions for the reparation and prevention of fibrotic lesional tissue. In his reply of 01.10.1999, the applicant has submitted technical data showing that at least some of the



Bescheid/Protokoll (Anlage)	Communication/Minutes (Annex)	Notification/Procès-verbal (Annexe)
Datum Date Date	29.11.2000	Blatt Sheet Feuille

2

Anmelde-Nr.: 94 916 710.0  
Application No.:  
Demande n°:

claimed compounds of present claim 10 show improved antifibrotic activity in vitro. These data prove that even minor structural changes of pirfenidone (D1) have considerable influence on the pharmacological activity.

The applicant's arguments concerning the previous objection under Art. 83 EPC allow the Examining Division to withdraw this objection.

The description remains to be adapted to the claims and D1 should be indicated in order to fulfill the requirements of R. 27(1)(b) EPC. The expression "which is hereby incorporated by reference" should be deleted (Guidelines C.II.4.18).

### **3. Conclusion**

The applicant is requested to file new claims which take account of the above comments and to adapt the description accordingly.

# WITHERS ROGERS

EUROPEAN & CHARTERED PATENT ATTORNEYS  
TRADE MARK ATTORNEYS

Golding House, 2 Hays Lane, London SE1 2HW

Tel: +44 (0)20 7663 3500 Fax: +44 (0)20 7663 3550

E-Mail: admin@withersrogers.com Web: www.withersrogers.com

DX: 39919 London Bridge South

European Patent Office  
Erhard Strasse 27  
D - 80298 München 2  
GERMANY

Our Ref: F5086/ISH/EC

Your Ref:

18 May 2000

BY FACSIMILE

TO CONTACT WRITER

TEL: +44 117 925 3030

Dear Sirs

**European Patent Application No. 94916710.0-2107**  
**MARGOLIN, Solomon B.**

We refer to the examination report dated 9 November 1999 in the above application and to the extension of the term for response dated 9 March 2000 and now enclose triplicate copies of replacement pages 24 and 25 of the specification as currently held on file by way of response. Existing pages 24 and 25 are hereby withdrawn without prejudice to their possible reinstatement at a later date.

In answer to the Examiner's objection that increased activity of the subject compounds cannot serve as a basis for inventive step across the whole range claimed, an amendment has been made to claim 1 (page 24) so that the N-phenyl-3-(1H) pyridones are no longer included. However, the claim is still directed to the N-phenyl-2-(1H) pyridones (excluding pirfenidone) since these have been demonstrated by the applicant to have unexpected properties which render the claimed matter inventive.

The Examiner has stated that the compounds in question represent only minor structural modifications of pirfenidone. The table of data submitted in the response dated 1 October 1999 shows convincingly that, no matter how 'minor' these modifications are, they can have an inordinate influence on the properties of the product compound. Thus, the hydroxylated analogue of pirfenidone shown in the table has virtually no detectable activity whilst the substitution or repositioning of the alkyl group in pirfenidone results in significantly active compounds. The former analogue has been deliberately excluded from claim 1 because of its inactivity. The latter group of species, however, have unexpectedly beneficial properties which, it is submitted, fully support the inventiveness of the claims subject matter. In opposition to this, the Examiner has further stated that only two of the relevant compounds have increased activity whereas one (the 3-methyl analogue) has identical activity and comparable toxicity to pirfenidone.

Ref S/2000

O LETTERS USR SV 5086.18-01-00

Partners: David Bannerman, Nicholas Wilson, Michael Blatchford, Michael Adkins, Adrian Chettie, Jeff Hogg, John Dean, Ben Dempster, Karl Barnfather, Ivor Harrison, David Pratt, Mark Armitage\*, Simon Beck, Catherine Ayers\*, Colin Jones, Howard Wright, David Croston, Consultant Partner: Peter Turner  
All partners are C.P.A. & E.P.A. unless indicated\*

Associates: Christopher Hey, Nigel Pamell, John Jones, David Elsy, David Fry, James Gray, Alex Duffield, Paul Derry, Matthew Allen, Keith Tait  
Practice Manager: Richard Clark, Accounts: Mary Sturges, Renewals: David Ayres (Manager), Mary Downey, Administration: Susan Savage,  
Translations: Rosemary Booth, Searching: Robin Webster, EP Formalities: Karen Austin

Also at 60 Holly Walk, Leamington Spa, Warwickshire CV32 4JE Tel: +44 (0)1926 336111 Fax: +44 (0)1926 335519  
1 Redcliff Street, Bristol BS1 6NP Tel: +44 (0)117 925 3030 Fax: +44 (0)117 925 3530 and  
Whitshill Chambers 23 Colmore Row Birmingham B3 2BL Tel: +44 (0)121 233 2997 Fax: +44 (0)121 236 2607

**WITHERS ROGERS**

European Patent Office

18 May 2000

Page 2

It is now submitted that, given that the 3-methyl analogue is at least as active as perfenidone and is certainly no more toxic, it should be accepted as contributing towards the inventive step of the invention defined by the amended claim. In the absence of evidence to the contrary, the benefit of doubt should be conferred on the applicant since there are many other properties of the claimed compounds that could not possibly be investigated owing to the need to file the application promptly. Thus, the 3-methyl analogue could yet be found to have far better pharmacokinetic properties *in vivo* than any of the other compounds, rendering the fact that it is at least as active as perfenidone *in vitro* of critical importance. Claim 1 is necessarily directed to the eventual use of the compounds *in vivo* and so it should be their unexpected potential efficacy in this setting that merits the grant of a patent. Without a reasonable breadth of patent protection, the further development of these compounds will be prejudiced, the consequences of which in terms of treatment of fibroses are considerable.


As a result of the amendment to claim 1, the -3-(IH)- pyridones have also been removed from the list in claim 10 (page 25). Claim 11 has been amended so that it recites only one compound, the highly active 5-ethyl-1-phenyl species.

The fact that all the examples in the description as filed refer only to perfenidone does not, it is submitted, amount to a 'serious lack of disclosure', as contended by the Examiner. The application as filed does not contravene Art. 83 EPC because it provides all the instruction that a skilled person would need in order to prepare and use the relevant compounds according to the claims. Preparative methods are incorporated by reference on page 1 (lines 22 to 27), whereas the treatment regimens for perfenidone in the examples provide ample guidance on the use of the compounds.

In summary, it is believed that the invention as defined in the amended claims involves an inventive step, the basis of which is the previously unforeseeable potential of the claimed compounds as anti-fibrotic agents for *in vivo* use. The application is also believed to disclose the invention sufficiently for the purposes of Art. 83 EPC.

It is requested that revision of the description may be deferred pending acceptance of the amended claims. As a precautionary measure, and in the event that the Examiner maintains his objections to the claims, the request for oral proceedings made in our letter of 1 October 1999 is hereby repeated.

Yours faithfully



I S Harrison  
WITHERS & ROGERS

Enc

await. conf.

22.05.00

J.S.

**Claims**

1. The use of a compound of the group N-phenyl-2-(1H) pyridones in the preparation of a medicament for the reparation and prevention of fibrotic lesional tissue in a mammal, with the proviso that the compound does not include 5-methyl-1-phenyl-2-(1H) pyridone.
2. The use according to claim 1, in which the compound is administered at a dosage from about 5 to 300 mg per kilogram of body weight per day.
3. The use according to claim 1, in which said compound is present in said medicament in an amount from 25 mg to 3200 mg.
4. The use according to claim 3, in which said compound is present in said medicament in an amount from 200 mg to 3200 mg.
5. The use according to any preceding claim, in which said fibrotic lesional tissue is associated with a condition in the group consisting of pulmonary fibrosis, benign prostate hypertrophy, coronary infarcts, cerebral infarcts, myocardiac fibrosis, musculoskeletal fibrosis, post-surgical adhesions, liver cirrhosis, renal fibrotic disease, fibrotic vascular disease, scleroderma, Alzheimer's disease, diabetic retinopathy, and skin lesions.
6. The use according to any preceding claim, in which said medicament is in the form of capsules, tablets, powders, granules, syrups, injectable fluids, and pills.
7. The use according to claim 1, in which the medicament is for topical administration and contains said compound in a concentration from 1 to 20% by weight.
8. The use according to claim 7, in which said fibrotic lesional tissue is associated with a condition in the group consisting of musculoskeletal fibrosis, post-surgical adhesions, scleroderma, glaucoma, and skin lesions.
9. The use according to claim 7 or claim 8, in which said medicament is in the form of creams, ointments, hydrophilic ointments, inhalable fluids, eye drops, and suppositories.

25

10. The use according to any preceding claim, in which said compound is selected from 3-methyl-1-phenyl-2-(1H)-pyridone, 6-methyl-1-phenyl-2-(1H) pyridone, 3,6-dimethyl-1-phenyl-2-(1H) pyridone, 5-ethyl-1-phenyl-2-(1H) pyridone, 1-phenyl-2-(1H)-pyridone and 1,3-diphenyl-5-methyl-2-(1H)-pyridone.
11. The use according to any preceding claim, in which the compound is 5-ethyl-1-phenyl-2-(1H) pyridone.

# WITHERS & ROGERS European Chartered Patent Attorneys, Trade Mark Attorneys

Goldings House, 2 Hays Lane, London SE1 2HW

36

## Partners

David Bannerman, B.Sc. (Chem.)  
Nicholas Wilson, F.I.T.M.A.  
Michael Blatchford, B.Sc. (Elec. Eng.)  
Michael Adkens, H.N.C (Aero. Eng.)  
Adrian Chettle, B.Sc., C.Eng.  
Jeff Hogg, B.Sc. (Phys.)  
John Dean, B.Sc. (Microbiol.)  
Ben Dempster, M.A. (Nat. Sc.)  
Ivor Harrison, C.Chem.  
David Pratt, B.Sc. (Phys.)  
Mark Armitage, B.Sc., LL.B., M.I.T.M.A.  
Karl Barnfather, B.Sc. (Phys.), Ph.D.  
Simon Beck, B.Sc. (Phys. & Elec. Eng.), Ph.D  
Catherine Ayers, M.A., M.I.T.M.A.  
Colin Jones, B.Sc. (Phys.), B.A.  
Howard Wright, B.Sc. (Phys.)  
David Croston, B.Eng. (Mech. Eng.)

Associates  
Christopher Hey, M.I.T.M.A.  
John Jones, B.Sc., C.P.A.  
David Elsy, B.Sc., Ph.D.  
David Fry, B.Eng., M.Sc.  
James Gray, B.Eng.  
Alex Duffield, B.A.  
Paul Derry, B.Eng.  
Matthew Allen, B.Eng., M.Sc.

Telephone: 0171 663 3500  
International: +44 171 663 3500

Fax: 0171 663 3550  
International: +44 171 663 3550

E-Mail: admin@withersrog.com  
Web: www.withersrogers.co.uk

DX: 39919 London Bridge South

## Consultant Partner:

Peter Turner, M.A., Ph.D., F.I.T.M.A.

All partners are C.P.A. & E.P.A. unless indicated.

Practice Manager: Richard Clark, M.Inst.A.M., MIMgt  
Accounts: Mary Sturgess  
Renewals: David Ayres (Manager)  
Mary Downey  
Administration: Susan Savage  
Translations: Rosemary Booth, B.Sc., M.I.T.I.  
Searching: Robin Webster, B.Eng.  
EP Formalities: Karen Austen

Our ref: F5086/ISH/EC

Your ref:

1 October 1999

TO CONTACT WRITER  
TEL: +44 117 925 3030

European Patent Office  
Erhard Strasse 27  
D - 80298 München 2  
GERMANY

Dear Sirs

**European Patent Application NO. 94916710.0-2107**  
Margolin, Solomon B.

We refer to the official letter dated 9th February 1999 and to the extension of the response term dated 21st June 1999 and now file replacement pages 24-26 of the specification containing amended claims 1 to 11 in triplicate. Claims 1 to 9 on file hitherto are now withdrawn.

Further processing is requested in a separate letter of today's date which also authorises deduction of the further processing fee from our deposit account.

The new claims are in second medical indication format and are directed to the use of N-phenyl-2-(1H) and 3-(1H) pyridones in the preparation of a medicament for treatment of fibrotic lesions. The claims specifically exclude the use of 5-methyl-1-phenyl-2-(1H)-pyridone (perfenidone) and are thus believed to define novel subject matter, in that the prior art describes only perfenidone for such use. The right of the applicant to revert to broader claims (still excluding pirenidone) is hereby reserved.

Although, as explained at length in the description, perfenidone has been shown to have remarkable efficacy in the treatment of conditions involving fibrotic lesions, analogous compounds have now been shown to be superior, either in terms of reduced toxicity, increased activity or both; in any event, they show an enhanced relative safety ratio. Surprisingly and despite the examiner's assertion to the contrary, even minor structural changes from that of perfenidone can significantly affect the properties, as the results presented in the following Table will demonstrate.

cont...

COMPOUND	RELATIVE ANTIFIBROTIC ACTIVITY*	ALBINO MICE I.P., LD <sub>50</sub>	RELATIVE SAFETY RATIO**
5-methyl-1-phenyl-2-(1H) pyridone (pirfenidone)	1.0	420	1.0
3-methyl-1-phenyl-2-(1H) pyridone	1.0	600	1.4
5-ethyl-1-phenyl-2-(1H) pyridone	8.0	500	9.5
3-ethyl-1-phenyl-2-(1H) pyridone	6.0	600	8.5
5-methyl-1-parahydroxyphenyl-2-(1H) pyridone	0.0	>2000	none

\* As measured by inhibition of proliferation and collagen synthesis by graded concentrations of the respective compounds when assayed in standard cultures of human fibroblast cells (WI38).

\*\* relative ratios determined by multiplying values in first two columns, divided by LD<sub>50</sub> figure for pirfenidone.

It is to be noted that the third and fourth compounds have activities eight and six times greater, respectively, than pirfenidone. Thus a dosage of one-eighth or one-sixth that of pirfenidone provides the same result, while greatly lowering the possible toxicity. The last compound, which is not within the scope of the present claims, has no activity.

The present invention provides a very powerful arrest of formation of, as well as causing removal of, pathogenic accumulation of water-insoluble collagenous connective tissue (for example, excessive scar or lesional fibrotic tissue). The powerful pyridones which are the subject of the present claims are effective at as much as eight times lower concentrations than pirfenidone, yet their acute toxicity does not differ significantly from that of pirfenidone. Consequently, not only are these agents more effective, they also afford an unexpected (8 to 10 fold) larger safety margin. The discovery of such greatly increased power for certain compounds is a wholly unexpected finding.

To enlarge on the description at page 19 line 7, idiopathic pulmonary fibrosis (IPF) is a progressive clinical syndrome of unknown etiology and fatal outcome. Currently available therapies are ineffective and associated with significantly adverse effects. Pirfenidone was investigated for its tolerability and usefulness in terminally ill patients with advanced IPF. Consecutive patients with IPF and deterioration despite conventional therapy or who were unable to tolerate or unwilling to try conventional therapy were treated with oral pirfenidone. Treatment was administered on a compassionate basis (open label). Fifty-four patients were followed for mortality, change in lung function, and adverse effects. Their mean age was 62, mean duration of symptoms 4.6 years, and time since lung biopsy was 3.2 years. Conventional therapy was discontinued in 38 of 46 patients; the other eight were able to decrease their prednisone dosage and eight had no previous conventional treatment.


One- and two-year survival was 78% (95% CI 55%, 89%) and 63% (95% CI 50%, 76%), respectively. Patients whose lung functions had deteriorated prior to enrolment appeared to stabilise after beginning treatment. Adverse effects were relatively minor. Compounds according to the present invention are significantly better than perfenidone and hold out more promise for more effective treatment of IPF.

In the light of the above, it is believed that the invention as now defined in the amended claims is novel and involves an inventive step.

It is required that revision of the description be deferred pending acceptance of the claims.

Oral proceedings are requested as a precaution.

Yours faithfully



I S Harrison  
WITHERS & ROGERS  
Enc

to examine

Exhibit

12. 10. 99 WT



EPA/EPO/OEB  
D-80298 München  
 +49 89 2399-0  
TX 523 656 epmu d  
FAX +49 89 2399-4465

Europäisches  
Patentamt  
Generaldirektion 2

European  
Patent Office  
Directorate General 2

Office européen  
des brevets  
Direction Générale 2

43

Harrison, Ivor Stanley  
Withers & Rogers,  
Goldings House, 2 Hays Lane  
London SE1 2HW  
GRANDE BRETAGNE

**Telephone Numbers:**

**Primary Examiner** +49 89 2399-8009  
(substantive examination)

**Formalities Officer / Assistant** +49 89 2399-8071  
(Formalities and other matters)



Application No. 94 916 710.0-2107	Ref. F5086/ISH/MDS	Date 09.11.99
Applicant MARGOLIN, Solomon B.		

**Communication pursuant to Article 96(2) and Rule 51(2) EPC**

The examination of the above-identified application has revealed that it does not meet the requirements of the European Patent Convention for the reasons enclosed herewith. If the deficiencies indicated are not rectified the application may be refused pursuant to Article 97(1) EPC.

You are invited to file your observations and insofar as the deficiencies are such as to be rectifiable, to correct the indicated deficiencies within a period

of 4 months

from the notification of this communication, this period being computed in accordance with Rules 78(3) and 83(2) and (4) EPC.

Amendments to the description, claims and drawings are to be filed where appropriate within the said period in three copies on separate sheets (Rule 36(1) EPC).

**Failure to comply with this invitation in due time will result in the application being deemed to be withdrawn (Article 96(3) EPC).**



LAFFARGUE-HAAK T  
Primary Examiner  
for the Examining Division

**EXRE coded**

04.11.99 St

Enclosure(s): 3 page/s reasons (Form 2906)

HS



Bescheid/Protokoll (Anlage)		Communication/Minutes (Annex)		Notification/Procès-verbal (Annexe)	
Datum Date Date	09.11.99	Blatt Sheet Feuille	1	Anmelde-Nr. Application No.: Demande n°:	94 916 710.0
**CODINGDATE**					

44

The examination is being carried out on the **following application documents**:

Text for the Contracting States:

AT BE CH LI DE DK ES FR GB GR IE IT LU NL PT SE

**Description, pages:**

1-8,12-15,19, as originally filed  
21-23

9-11,16-18,20 as received on 05.12.1995 with letter of 30.11.1995

**Claims, No.:**

1-11 as received on 08.10.1999 with letter of 01.10.1999

**Drawings, sheets:**

1/1 as originally filed

**1. Amendments**

The amendments filed (i.e. new claims 1-11) are allowable under Art. 123(2) EPC.

**2. Novelty and inventive step (Cl. 1-11)**

Inclusion of a disclaimer in independent claim 1 overcomes the novelty objection with respect to D1 and the subject-matter of claims 1-11 meets the requirements of Art. 54 EPC.

However, new claims 1-11 fail to meet the requirements of Art. 56 EPC for the following reasons. D1 (closest prior art) discloses the use of 5-methyl-1-phenyl-2-(1H)-pyridone (= pirfenidone) for the treatment of fibrosis. The difference with the present application is the use of structurally close derivates of N-phenyl-2-(1H)-pyridones (excepted pirfenidone) and N-phenyl-3-(1H)-pyridones for the same medical indication. The technical problem would be to provide alternative compounds for the treatment of fibrosis. As stated in a previous communication, the solution provided by the present application refers to minor structural modifications of pirfenidone (methyl substituent on position 3 and/or 6, instead of 5 ;



Beschluß/Protokoll (Anlage)	09.11.99	Communication/Minutes (Annex)	Notification/Procès-verbal (Annexe)
Datum Date Date	**CODINGDATE**	Blatt Sheet Feuille	2

45

Anmelde-Nr.  
Application No..  
Demande n°: 94 916 710.0

replacement of 5-methyl by 5-ethyl ; C=O on position 2 or 3) and is therefore obvious for the skilled person.

With his reply, the applicant submitted comparative tests for 3 claimed compounds (all 2-(1H) derivatives) which tended to show an enhanced relative safety ratio for the claimed compounds, as compared to pirfenidone. There appears to be an error with respect to the cited LD50 ("420 mg/kg"), in the light of present description (p. 9) and D1 (both "600 mg/kg"). This implies that the acute toxicity for all tested compounds is comparable (500-600 mg/kg), whereas the relative antifibrotic activity varies from 1.0 to 8.0. Increased activity cannot serve as a basis for an inventive step **in the whole range claimed**, as the submitted data clearly demonstrate that one claimed compound (3-Me-1-Phe-2-(1H) pyridone) has an identical activity and two claimed compounds (5 or 3-Et-1-Phe-2-(1H) pyridone) have increased activity as compared with pirfenidone. No data were submitted with respect to 3-(1H) derivatives. The clinical data concerning the treatment of idiopathic pulmonary fibrosis (p. 19 description and p. 2-3, Applicant's reply of 01.10.1999) are not sufficiently clear with respect to tested compounds (only pirfenidone ??) and can therefore not be taken into consideration for inventive step.

In conclusion, the subject-matter of claims 1-11 fails to meet the requirement of Art. 56 EPC.

### 3. Lack of disclosure

The applicant's attention is drawn to the fact that all examples in the description refer to pirfenidone. As this compound is disclaimed in the present set of claims, a serious lack of disclosure is foreseen (Art. 83 EPC).

### 4. Conclusion

It is not at present apparent which part of the application could serve as a basis for a new, allowable claim. Should the applicant insist in maintaining the present set of claims, refusal of the application under Art. 97(1) EPC for the reasons outlined above should be expected. In this context the applicant is invited to indicate whether he maintains his request for oral proceedings.



EPA/EPO/OEB  
D-80298 München  
089/2399-0  
TX 523 656 epmu d  
FAX 089/2399-4465

Europäisches  
Patentamt

Generaldirektion 2

European  
Patent Office

Directorate General 2

Office européen  
des brevets

Direction Générale 2

COPY

Harrison, Ivor Stanley  
Withers & Rogers,  
Goldings House, 2 Hays Lane  
London SE1 2HW  
GRANDE BRETAGNE



Datum/Date

28.10.99

Zeichen/Ref/Réf <b>F5086/ISH/MDS</b>	Anmeldung Nr./Application No./Demande n° /Patent Nr./Patent No./Brevet n°. <b>94916710.0-2107/US9405156</b>
Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire <b>MARGOLIN, Solomon B.</b>	

#### DECISION ON FURTHER PROCESSING UNDER ARTICLE 121 (3) EPC

Following examination of the request for further processing received on 01.10.99 it has been decided that processing of the above-mentioned European patent application will be resumed.

The finding notified in the communication dated 20.09.99 that the application was deemed to be withdrawn is revoked.

The refusal of the application dated ..... is revoked.

The procedure will be continued.

*BH*  
Formalities Officer  
Tel. No.: 089/2399-8071  
Waltraud Hébert 28.10.99 HT

# WITHERS & ROGERS European & Chartered Patent Attorneys, Trade Mark Attorneys

Goldings House, 2 Hays Lane, London SE1 2HW

**Partners**

David Banerjee, B.Sc. (Chem.)  
 Nicholas Wilson, F.I.T.M.A.  
 Michael Blanchard, B.Sc. (Elec. Eng.)  
 Michael Addins, M.N.C. (Aero Eng.)  
 Adrian Chettle, B.Sc., C.Eng.  
 Jeff Hogg, B.Sc. (Phys.)  
 John Dean, B.Sc. (Microbial.)  
 Ben Dampner, M.A. (Nat. Sc.)  
 Ivar Harrison, C.Chem.  
 David Pran, B.Sc. (Phys.)  
 Mark Armitage, B.Sc., LL.B., M.I.T.M.A.  
 Karl Barnsleher, B.Sc. (Phys.), Ph.D.  
 Simon Beck, B.Sc. (Phys. & Elec. Eng.), Ph.D.  
 Catherine Ayres, M.A., M.I.T.M.A.  
 Colin Jones, B.Sc. (Phys.), B.A.  
 Howard Wright, B.Sc. (Phys.)  
 David Croston, B.Eng. (Mech. Eng.)

**Associates**

Christopher Hay, M.I.T.M.A.  
 John Jones, B.Sc., C.F.A.  
 David Eley, B.Sc., Ph.D.  
 David Fry, B.Eng., M.Sc.  
 James Gray, B.Eng.  
 Alex Duffield, B.A.  
 Paul Derry, B.Eng.  
 Matthew Allen, B.Eng., M.Sc.

Telephone: 0171 663 3500  
 International: +44 171 663 3500

Fax: 0171 663 3550  
 International: +44 171 663 3550

E-Mail: admin@withersrog.com  
 Web: www.withersrogers.co.uk

DX: 39919 London Bridge South

**Consultant Partner:**

Peter Turner, M.A., Ph.D., F.I.T.M.A.

All partners are C.P.A. & C.F.A. unless indicated.

**Practices Manager:** Richard Clark, M.Inst.A.M., MIMgt.  
**Account:** Mary Sturges  
**Renewals:** David Ayres (Manager)  
**Administration:** Mary Downey  
**Translations:** Susan Savage  
**Searching:** Rosemary Booth, B.Sc., M.I.T.I.  
**EP Formalities:** Robin Webster, B.Eng.  
**EP Formalities:** Karen Austin

Our ref: F5086/ISH/EC

Your ref:

1 October 1999

**BY FAX**

European Patent Office  
 Erhard Strasse 27  
 D - 80298 München 2  
 GERMANY

Dear Sirs

European Patent Application No. 94916710.0-2107  
 Margolin, Solomon B.

We refer to the notification of loss of rights dated 20th September 1999 in the above application and hereby request further processing. Please withdraw the fee for further processing of €76 from our deposit account number 2805.0082.

A response to the official letter dated 9th February 1999 is being filed separately.

Yours faithfully

I S Harrison  
 WITHERS & ROGERS

cc: Accounts

RFP R 1  
 awaiting payment  
 and response

05.10.99 HT



EPA/EPO/OEB  
D-80298 München  
089/2399-0  
TX 523 656 epmu d  
FAX 089/2399-4465

Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

Generaldirektion 2

Directorate General 2

Direction Générale 2

**COPY**

34

Harrison, Ivor Stanley  
Withers & Rogers,  
Goldings House, 2 Hays Lane  
London SE1 2HW  
GRANDE BRETAGNE



Datum/Date

**20.09.99**

Zeichen/Ref./Réf. <b>F5086/ISH/MDS</b>	Anmeldung Nr./Application No./Demande n°/Patent Nr./Patent No./Brevet n° <b>94916710.0-2107</b>
Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire <b>MARGOLIN, Solomon B.</b>	

**NOTING OF LOSS OF RIGHTS (RULE 69(1) EPC)**

The European Patent application is deemed to be withdrawn under Article 96(3) EPC,

because the invitation to file observations on the communication from the Examining Division dated 09.02.99

was not complied with.

**Request for decision:**

If the applicant considers that this finding is inaccurate, he may, within (a non-extendable period of) TWO MONTHS after notification of this communication, apply in writing for a decision on the matter by the European Patent Office (Rule 69(2) EPC). The application can only lead to the finding being reversed, if this does not actually correspond to the factual or legal situation.

**Further processing of the application:**

The legal consequence that the application is deemed withdrawn will be retracted if within (a non-extendable period of) TWO MONTHS after notification of this communication further processing of the European patent application under Article 121 EPC is requested in writing, the fee for further processing is paid in accordance with the Rules Relating to Fees, and the omitted act is completed.

**For the Examining Division:**

LAUSENMEYER J

Tel. No.: (+49-89) 2399-8074





[ ] EPA/EPO/OEB  
D-80298 Munchen  
P (089) 2399-0  
TX 523 656 epmu d  
FAX (089) 2399-4465

Europäisches  
Patentamt

Generaldirektion 2

European  
Patent Office

Directorate General 2

Office européen  
des brevets

Direction Générale 2

Harrison, Ivor Stanley  
Withers & Rogers,  
Goldings House, 2 Hays Lane  
London SE1 2HW  
GRANDE BRETAGNE

Telephone Numbers:

Primary Examiner (substantive examination) (089) 2399-8009

Formalities Officer / Assistant (Formalities and other matters) (089) 2399-8071



Application No 94 916 710.0-2107	Ref F5086/ISH/MDS	Date
Applicant MARGOLIN, Solomon B.	0 9.02.99	

**Communication pursuant to Article 96(2) and Rule 51(2) EPC**

The examination of the above-identified application has revealed that it does not meet the requirements of the European Patent Convention for the reasons enclosed herewith. If the deficiencies indicated are not rectified the application may be refused pursuant to Article 97(1) EPC.

You are invited to file your observations and insofar as the deficiencies are such as to be rectifiable, to correct the indicated deficiencies within a period

of 4 months

from the notification of this communication, this period being computed in accordance with Rules 78(3) and 83(2) and (4) EPC.

Amendments to the description, claims and drawings are to be filed where appropriate within the said period in **three copies** on separate sheets (Rule 36(1) EPC).

**Failure to comply with this invitation in due time will result in the application being deemed to be withdrawn (Article 96(3) EPC).**



LAFFARGUE-HAAK T  
Primary Examiner  
for the Examining Division

EXRE coded

0 9.02.99 Bt

Enclosure(s): 2 page/s reasons (Form 2906)



Beschreibung/Protokoll (Anlage)	Communication/Minutes (Annex)	Notification/Procès-verbal (Annexe)
Datum Date Date	Blatt Sheet Feuille	Anmelde-Nr.: Application No.. Demande n°:
09.12.99	1	94 916 710.0

The examination is being carried out on the **following application documents**:

Text for the Contracting States:

AT BE CH LI DE DK ES FR GB GR IE IT LU NL PT SE

**Description, pages:**

1-8,12-15,19,	as originally filed
21-23	
9-11,16-18,20	as received on 05.12.1995 with letter of 30.11.1995

**Claims, No.:**

1-11	as received on 05.12.1995 with letter of 30.11.1995
------	-----------------------------------------------------

**Drawings, sheets:**

1/1	as originally filed
-----	---------------------

**1. Amendments**

The amendments (claims and description) submitted by the applicant with a letter dated 30.11.1995 and received 05.12.1995, are allowable with respect to Art. 123(2) EPC.

**2. Documents cited**

The following documents (D) are referred to in this communication; the numbering will be adhered to in the rest of the procedure:

- D1 : EP-A2-383 591
- D2 : US-A-3 974 281 (cited in the application)
- D3 : US-A-4 042 699 (cited in the application)

**3. Lack of novelty and inventive step (Cl. 1-11)**

D1 discloses the use of 5-methyl-1-phenyl-2(1H)-pyridone (=pirfenidone) for the prevention and treatment of fibrotic lesions and anticipates the subject-matter of claims 1-8 and 10-11.

Datum  
Date  
Date

09.02.93

Blatt  
Sheet  
Feuille

2

Anmelde-Nr.  
Application No.  
Demande n°:

94 916 710.0

D2 (Ex. 2-30) and D3 (Ex. 3, 4, 6, 7, 12-14) disclose pharmaceutical compositions containing N-substituted 2-(1H) pyridones and therefore anticipate the subject-matter of claim 9. The applicant is reminded that the presently worded claim 9 refers to pharmaceutical compositions per se and not to the use of this composition for treating a particular disease (see also Guidelines C-IV.4.2).

Even if novel subject-matter could be established (e.g. claiming only N-substituted 3-(1H) pyridones), the present application does not meet the requirements of Articles 52(1) and 56 EPC, because the lack of inventive step. The technical problem with respect to D1 (closest prior art), would be to provide substances for treating fibrosis other than N-substituted 2-(1H) pyridones. As the present invention refers to N-substituted 3-(1H) pyridones, which are structurally close, it would have been obvious for the skilled person to introduce a minor structural change in order to solve the technical problem. Unless the applicant can demonstrate a surprising effect, which does not appear from the application as filed, the subject-matter of claim 1-11 also lacks an inventive step.

#### 4. Concluding remarks

It is not at present apparent which part of the application could serve as a basis for a new, allowable claim. Should the applicant nevertheless regard some particular matter (e.g. N-substituted 3-(1H) pyridones) as patentable an independent claim including such matter should be filed taking account of Rule 29(1) EPC.

Tanneke Haak